



Pharma  
绿叶制药

Luye Pharma Group Ltd.

绿叶制药集团有限公司

*(incorporated in Bermuda with limited liability)*

Stock Code: 2186



# 2021

## INTERIM REPORT

# CONTENTS

- 02** Company Overview
- 03** Corporate Information
- 05** Financial Highlights
- 06** Management Discussion and Analysis
- 22** Other Information
- 27** Review Report of Interim Financial Information
- 28** Interim Condensed Consolidated Statement of Profit or Loss
- 29** Interim Condensed Consolidated Statement of Comprehensive Income
- 30** Interim Condensed Consolidated Statement of Financial Position
- 32** Interim Condensed Consolidated Statement of Changes in Equity
- 34** Interim Condensed Consolidated Statement of Cash Flows
- 36** Notes to the Interim Condensed Consolidated Financial Information

# COMPANY OVERVIEW

The Group focuses on developing, producing, marketing and selling innovative pharmaceutical products in four of the largest and fast growing therapeutic areas in the People's Republic of China ("PRC" or "China"), the United States ("the U.S."), Europe and other countries or districts, namely oncology, central nervous system ("CNS"), cardiovascular system, alimentary tract and metabolism. The Group has a portfolio of over 30 products, covering over 80 countries and regions around the world, including large pharmaceutical markets — China, the U.S., Europe and Japan, as well as fast growing emerging markets.

The Group has established an extensive nationwide sales and distribution network and sold its products to 30 provinces, autonomous regions and municipalities throughout the PRC in the first half of 2021. The Group's sales, marketing and distribution functions are conducted through around 1,000 sales and marketing personnel, a network of approximately 1,850 distributors that collectively enabled the Group to sell its products to over 18,800 hospitals. For international markets, The business of the Group covers 80 countries or regions including the U.S., countries in the European Union (EU), Japan, Association of Southeast Asian Nations ("ASEAN"), Latin America, Gulf Cooperation Council ("GCC") region and other emerging countries or regions. The Group also has strong sales partnerships with more than 50 partners throughout the world.

The Group's R&D activities are organised around four platforms in the chemical drug sector — long acting and extended release technology, liposome and targeted drug delivery, transdermal drug delivery systems and new compounds. The Group has expanded its R&D capability to biological sector supported by Shandong Boan Biological Technology Co., Ltd.'s ("Boan Biotech") three cutting-edge platforms, namely Human Antibody Transgenic Mouse and Phage Display Technology, Bispecific T-cell Engager Technology and ADC Technology Platform. The Group balances clinical development risks by strategically allocating its resources between proprietary formulations of proven compounds and new chemical entities as well as biosimilars and novel antibodies. The Group believes that its R&D capabilities will be the driving force behind the Group's long-term competitiveness, as well as the Group's future growth and development.

As at 30 June 2021, the Group's R&D team consisted of 856 employees, including 82 Ph.D. degree holders and 430 Master's degree holders in medical, pharmaceutical and other related areas.

As at 30 June 2021, the Group had been granted over 235 patents and had over 74 pending patent applications in the PRC, as well as over 595 patents and over 119 pending patent applications overseas.

As at 30 June 2021, the Group had 33 PRC pipeline product candidates in various stages of development. These candidates included 13 oncology products, 13 CNS products and 7 other products. the Group had 13 pipeline product candidates in the U.S., Europe and Japan in various stages of development.

# CORPORATE INFORMATION

## BOARD OF DIRECTORS

### Executive Directors

Mr. LIU Dian Bo  
*(Executive Chairman and Chief Executive Officer)*  
Mr. YANG Rong Bing *(Vice Executive Chairman)*  
Mr. YUAN Hui Xian  
Ms. ZHU Yuan Yuan

### Non-executive Directors

Mr. SONG Rui Lin  
Mr. SUN Xin (appointed on 8 February 2021)

### Independent Non-executive Directors

Mr. ZHANG Hua Qiao  
Professor LO Yuk Lam  
Mr. LEUNG Man Kit  
Mr. CHOY Sze Chung Jojo

## COMPANY SECRETARY

Ms. LEE Mei Yi

## AUTHORIZED REPRESENTATIVES

Mr. YANG Rong Bing  
Ms. ZHU Yuan Yuan

## AUDIT COMMITTEE

Mr. LEUNG Man Kit *(Chairman)*  
Mr. ZHANG Hua Qiao  
Professor LO Yuk Lam

## REMUNERATION COMMITTEE

Mr. CHOY Sze Chung Jojo *(Chairman)*  
Mr. ZHANG Hua Qiao  
Professor LO Yuk Lam

## NOMINATION COMMITTEE

Professor LO Yuk Lam *(Chairman)*  
Mr. ZHANG Hua Qiao  
Mr. CHOY Sze Chung Jojo

## REGISTERED OFFICE

Clarendon House  
2 Church Street  
Hamilton HM 11  
Bermuda

## HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN THE PEOPLE'S REPUBLIC OF CHINA

No. 15 Chuang Ye Road  
High-tech Industrial Development Zone  
Yantai, Shandong  
People's Republic of China  
(postal code: 264003)

22/F, Gubei International Fortune Center II  
Hongqiao Road 1438  
Changning District  
Shanghai  
People's Republic of China

## PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Unit 3207, 32/F, Champion Tower  
3 Garden Road  
Central  
Hong Kong

## PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Codan Services Limited  
Clarendon House  
2 Church Street  
Hamilton HM 11  
Bermuda

# CORPORATE INFORMATION

## HONG KONG SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited  
Shops 1712–1716  
17th Floor, Hopewell Centre  
183 Queen's Road East  
Wanchai  
Hong Kong

## LEGAL ADVISERS

Allen & Overy  
9/F, Three Exchange Square  
Central  
Hong Kong

Conyers Dill & Pearman  
2901 One Exchange Square  
8 Connaught Place  
Central  
Hong Kong

## AUDITOR

Ernst & Young  
*Certified Public Accountants*  
*Registered Public Interest Entity Auditor*  
27/F, One Taikoo Place  
979 King's Road  
Quarry Bay  
Hong Kong

## STOCK CODE

2186

## COMPANY'S WEBSITE

[www.luye.cn](http://www.luye.cn)

## PRINCIPAL BANKERS


Bank of China Limited  
China Everbright Bank  
Industrial and Commercial Bank of China Limited  
Citibank (China) Limited

# FINANCIAL HIGHLIGHTS


- Revenue decreased by RMB10.5 million or 0.4% to RMB2,951.7 million, as compared to the six months ended 30 June 2020.
- Gross profit decreased by RMB244.2 million or 11.1% to RMB1,953.7 million, as compared to the six months ended 30 June 2020, and gross profit margin was 66.2%.
- Net profit decreased by RMB132.3 million or 24.5% to RMB408.0 million, as compared to the six months ended 30 June 2020.
- Profit attributable to shareholders decreased by RMB152.8 million or 28.3% to RMB386.6 million, as compared to the six months ended 30 June 2020.
- EBITDA decreased by RMB207.6 million or 17.9% to RMB954.7 million, as compared to the six months ended 30 June 2020.
- Earnings per share was RMB11.32 cents compared to RMB16.90 cents for the six months ended 30 June 2020.
- No interim dividend was proposed by the Board for the six months ended 30 June 2021.

	2017 RMB Million Restated	2018 RMB Million Restated	2019 RMB Million Restated	2020 RMB Million	30 June 2020 RMB Million	<b>30 June 2021 RMB Million</b>
Revenue	3,814.8	5,172.5	6,357.9	5,539.6	2,962.2	<b>2,951.7</b>
Gross Profit	2,963.4	4,049.4	4,879.2	3,990.6	2,197.9	<b>1,953.7</b>
EBITDA	1,273.0	1,893.1	2,385.1	1,877.1	1,162.2	<b>954.7</b>
Net Profit	827.5	1,204.9	1,354.1	703.3	540.3	<b>408.0</b>
Profit attributable to owners of the Parent	909.6	1,202.3	1,396.2	706.6	539.4	<b>386.6</b>
Total Assets	10,876.3	17,702.9	19,407.7	20,630.6	19,564.9	<b>21,844.1</b>
Total Liability	4,191.1	10,082.6	10,487.3	12,531.6	11,742.2	<b>12,146.4</b>
Equity	6,685.2	7,620.3	8,920.4	8,099.0	7,822.7	<b>9,697.7</b>

30 June 2020



30 June 2021



# MANAGEMENT DISCUSSION AND ANALYSIS

## BUSINESS OVERVIEW

The Group focuses on developing, producing, marketing and selling innovative pharmaceutical products in four of the largest and fastest growing therapeutic areas in the People's Republic of China ("PRC" or "China"), the United States ("the U.S."), Europe and other emerging countries or districts, namely oncology, central nervous system ("CNS"), cardiovascular system, alimentary tract and metabolism. The Group has a portfolio of over 30 products, covering over 80 countries and regions around the world, including large pharmaceutical markets — China, the U.S., Europe and Japan, as well as fast growing emerging markets. During the six months ended 30 June 2021, the Group's business was influenced by the pandemic of novel coronavirus disease 2019 ("COVID-19") and global economic fluctuations but still maintained stability. The Group recorded a revenue decrease of 0.4% in the first half of 2021 as compared to that of 2020. The Group continually invests in Research and Development ("R&D") to maintain its competitiveness, and has a robust product pipeline including 33 China pipeline product candidates and 13 pipeline product candidates in the U.S., Europe and Japan.

## MARKET POSITIONING

In China, the Group's key products are competitively positioned in four key therapeutic areas and have gained top-ranking market shares measured by revenue. According to IQVIA, oncology-related pharmaceutical products constituted the largest market in China for pharmaceutical products in the first half of 2021. The Group's portfolio of oncology products includes Lipusu, the first and only paclitaxel liposome product approved for sale globally as of 30 June 2021, as well as CMNa, a Class I New Chemical Drug and the only China National Medical Products Administration (the "NMPA", formerly known as the China Food and Drug Administration) approved sensitiser for cancer radiotherapy in China. IQVIA data showed that cardiovascular system-related pharmaceutical products constituted the fourth largest market for pharmaceutical products in the PRC in the first half of 2021. According to IQVIA, the Group's key cardiovascular system products, Xuezhikang and Maitongna, were the most popular natural medicine for the treatment of hypercholesterolaemia and the fourth largest vasoprotective pharmaceutical product in China in the first half of 2021, respectively. According to IQVIA, alimentary tract and metabolism-related pharmaceutical products constituted the second largest market for pharmaceutical products in the PRC in the first half of 2021. According to IQVIA, the Group was the second largest domestic pharmaceutical manufacturer of oral diabetic medications in China in the first half of 2021 measured by revenue. IQVIA data showed that CNS-related pharmaceutical products constituted the fifth largest market for pharmaceutical products in the PRC in the first half of 2021. The Group's key product Seroquel was the fifth largest product in schizophrenia therapeutic area and the largest quetiapine product in terms of sales in the PRC in the first half of 2021.

For international markets, the Group's products are mainly positioned in CNS therapeutic area, including Seroquel, Seroquel XR, Rivastigmine once-daily transdermal patch, Rivastigmine multi-day transdermal patch, Fentanyl patches and Buprenorphine patches.

For the six months ended 30 June 2021, the Group's revenue from cardiovascular system products increased by 86.4% to RMB800.7 million. Revenue from alimentary tract and metabolism products increased by 17.1% to RMB458.3 million. Revenue from sales of oncology products decreased by 30.5% to RMB927.0 million. Revenue from CNS products decreased by 7.0% to RMB694.4 million.

## KEY PRODUCTS

The Company believes that the Group's seven key products are competitively positioned for high prevalence medical conditions that are expected to grow stably globally.

### Lipusu<sup>®</sup> (力撲素<sup>®</sup>)

Lipusu is the Group's proprietary formulation of paclitaxel using an innovative liposome injection delivery vehicle and a chemotherapy treatment of certain types of cancer. As of 30 June 2021, Lipusu represented the first and only paclitaxel liposome product approved for sale globally. In December 2020, Lipusu has been included in the category B of the new Catalogue of National Reimbursement Drug List ("NRDL"). All indications of Lipusu, including non-small cell lung cancer, ovarian and breast cancer, are reimbursed under the NRDL. The 2020 NRDL has come into effect in March 2021.

### CMNa<sup>®</sup> (希美納<sup>®</sup>)

CMNa is sodium glycididazole, a proprietary compound that the Group prepares in injectable form and is indicated for use in connection with radiotherapy for certain solid tumours. It is a Class I New Chemical Drug and the only NMPA approved sensitiser for cancer radiotherapy in China. According to the NMPA, CMNa was the only glycididazole product available for sale in the first half of 2021. An independent third party study in 2009 concluded that the use of CMNa for the treatment of certain cancers increased the probability of complete or partial remission and reduced overall treatment costs.

### Xuezhikang<sup>®</sup> (血脂康<sup>®</sup>)

Xuezhikang is the Group's proprietary natural medicine derived from red yeast rice indicated for hypercholesterolaemia. According to the NMPA, the Group was the only Xuezhikang manufacturer in China as of 30 June 2021. According to IQVIA, the market for lipid-regulating drugs in China was estimated to be approximately RMB4.6 billion in the first half of 2021. According to IQVIA, Xuezhikang ranked as the most popular natural medicine for the treatment of hypercholesterolaemia and the fourth largest lipid-regulating drug in China in the first half of 2021.

### Maitongna<sup>®</sup> (麥通納<sup>®</sup>)

Maitongna is sodium aescinate in injectable form and is indicated for the treatment of cerebral edema and edema caused by trauma or surgery as well as for the treatment of venous reflux disorder. According to IQVIA, the market for vasoprotective pharmaceutical products in China was estimated to be approximately RMB1.9 billion in the first half of 2021. Maitongna was the best-selling sodium aescinate product in China in the first half of 2021 and ranked as the third largest domestically manufactured vasoprotective pharmaceutical product in China in the first half of 2021.

### Bei Xi<sup>®</sup> (貝希<sup>®</sup>)

Bei Xi is acarbose in capsule form and is indicated for lowering blood glucose in patients with type 2 diabetes mellitus. According to the NMPA, the Group was the only manufacturer of acarbose in capsule form in the first half of 2021. According to IQVIA, the market for acarbose products in China was estimated to be approximately RMB0.6 billion in the first half of 2021 and Bei Xi ranked as the second largest domestic pharmaceutical manufacturer of oral diabetic medications in China in the first half of 2021 measured by revenue.

## Rivastigmine Transdermal Patches (the “Rivastigmine Patch”)

The Rivastigmine Patch is rivastigmine in transdermal patches form approved in China, the U.S., Europe and other emerging countries or regions, indicated for mild to moderate dementia of the Alzheimer’s type and dementia due to Parkinson’s disease.

## Seroquel® (思瑞康®) and Seroquel XR® (思瑞康緩釋片®)

Seroquel (quetiapine fumarate, immediate release, IR) and Seroquel XR (extended release formulation) are atypical antipsychotic medicines with antidepressant properties. The main indications for Seroquel are the treatment of schizophrenia and bipolar disorder. Seroquel XR is also approved in some markets for major depressive disorder and generalised anxiety disorder. According to IQVIA, Seroquel was the fifth largest product in schizophrenia therapeutic area and the largest quetiapine product in the PRC in the first half of 2021. In addition to China, Seroquel and Seroquel XR are also marketed by the Group in other 50 developed and emerging countries.

## RESEARCH AND DEVELOPMENT

The Group’s R&D activities are organised around four platforms in the chemical drug sector — long acting and extended release technology, liposome and targeted drug delivery, transdermal drug delivery systems and new compounds. The Group has expanded its R&D capability to biological sector supported by Boan Biotech’s three cutting-edge platforms, namely Human Antibody Transgenic Mouse and Phage Display Technology, Bispecific T-cell Engager Technology and ADC Technology Platform. The Group balances clinical development risks by strategically allocating its resources between proprietary formulations of proven compounds and new chemical entities as well as biosimilars and novel antibodies. The Group believes that its R&D capabilities will be the driving force behind the Group’s long-term competitiveness, as well as the Group’s future growth and development. As at 30 June 2021, the Group’s R&D team consisted of 856 employees, including 82 Ph.D. degree holders and 430 Master’s degree holders in medical, pharmaceutical and other related areas. As at 30 June 2021, the Group had been granted over 235 patents and had over 74 pending patent applications in the PRC, as well as over 595 patents and over 119 pending patent applications overseas.

The Group will continue to invest the products in four strategic therapeutic areas — oncology, CNS, cardiovascular and alimentary tract and metabolism. As at 30 June 2021, the Group had 33 PRC pipeline product candidates in various stages of development. These candidates included 13 oncology products, 13 CNS products and 7 other products.

Also, the Group had 13 pipeline product candidates in the U.S., Europe and Japan in various stages of development. In the U.S., two pipeline product candidates (LY03004 and LY03005) have filed New Drug Application (“NDA”) and 4 pipeline product candidates (LY03003, LY03010, LY06006/LY01011) are in different clinical trial stages. In Europe, one pipeline product candidate (LY30410) is eligible for marketing authorization in several European Union (“EU”) countries and 4 products (LY30990, LY03004, LY06006/LY01011) are under different clinical trial stages. In Japan, 3 pipeline product candidates (LY03003, LY03005, LY30410) are under clinical trial stages.

# MANAGEMENT DISCUSSION AND ANALYSIS

For global R&D progress:

In January 2021, the Group's monthly microspheres injection product candidate LY03009, commenced phase I clinical trial in Australia. LY03009 is one of the Group's key CNS product candidates developed on a long acting and extended-release formulation platform, indicated for Parkinson's Disease (PD) and moderate to severe restless legs syndrome (RLS).

In January 2021, the phase I clinical trial of the Rotigotine Extended Release Microspheres for injection (LY03003) completed in Japan. LY03003 is one of the Group's key innovative product candidates of CNS developed on a long acting and extended-release formulation platform. The drug is being developed concurrently in the markets of China, the U.S., Europe, Japan and several other countries or regions. It is under phase III clinical trial in China and the U.S.. LY03003 delivers medication by weekly intramuscular injection. This is the first product worldwide to produce long-term Continuous Dopamine Stimulation (CDS).

In May 2021, the Decentralised Registration Procedures ("DCPs") in the EU in relation to the Marketing Authorization Applications ("MAA") for Rivastigmine Multi-Day Transdermal Patch ("Rivastigmine MD" or "LY30410") was completed. Rivastigmine MD is an innovative delivery system drug being developed by the Group for the treatment of mild to moderate dementia associated with Alzheimer's disease. Since the DCPs had completed on 21 May 2021, the Rivastigmine MD is now eligible for Marketing Authorizations ("MA") by individual member states of the EU involved in the DCPs.

In August 2021, the Group has submitted the investigational new drug ("IND") application for its new CNS drug LY03015 to the Food and Drug Administration ("FDA") of the U.S.. LY03015 is an innovative small molecule compound product indicated for the treatment of tardive dyskinesia ("TD") and Huntington's disease ("HD"), developed by the Group. LY03015 is a new generation VMAT2 inhibitor, and can reduce the symptoms of TD and HD by inhibiting the release of presynaptic dopamine ("DA"), preventing the stimulation of supersensitive D2 receptors by DA without blocking D2 receptors in the postsynaptic membrane.

For China R&D progress:

In January 2021, the marketing registration of Risperidone Microspheres for Injection (II) ("LY03004", Rykindo<sup>®</sup>) was approved by the NMPA. It was the first innovative formulation developed under the Group's long acting and extended technology platform that received marketing approval. Rykindo<sup>®</sup>/LY03004 is an extended-release microspheres for injection administered bi-weekly for the treatment of schizophrenia.

In March 2021, the clinical trial application of the Group's Class 2 new drug, Ropivacaine Hydrochloride Liposome Suspension Injection ("LY09606"), has received formal acceptance from the 中國國家藥品監督管理局藥品審評中心 (China Centre For Drug Evaluation of National Medical Products Administration) (the "CDE"). LY09606 is a multivesicular liposome formulation containing Ropivacaine. Its unique multivesicular structure facilitates the sustained release of the encapsulated drug. LY09606, which can be indicated for postoperative analgesia, is the first Ropivacaine multivesicular liposome injection product which has applied for clinical trial approval in China. The high technical barriers and complex processes of multivesicular liposome manufacturing attest to the Group's strengths in key technologies for liposome research, development and manufacturing. In May 2021, LY09606 has obtained approval from the CDE to initiate clinical trials.

In March 2021, the Group's Class 1 new drug LPM3480392 injection ("LY03014") commenced enrolment of subjects in phase I clinical trial in China. LY03014 is a small molecule Gi protein biased at mu-opioid receptor (MOR) agonist, indicated for the treatment of postoperative moderate-to-severe acute pain and breakthrough cancer pain.

## MANAGEMENT DISCUSSION AND ANALYSIS

In March 2021, a phase III clinical trial of the Group's Class 1 new chemical entity (NCE) product Anshufaxine Hydrochloride Extended-release Tablets ("LY03005") in the treatment of Major Depressive Disorder (MDD) in China met the predefined endpoints. LY03005 is a new antidepressant agent developed by the new therapeutic entity/new chemical entity (NTE/NCE) technology platform of the Group. Studies reveal that Anshufaxine is a serotonin (5-HT)-norepinephrine (NE)-dopamine (DA) reuptake inhibitor (SNDRIs). In June 2021, the marketing authorization application of LY03005 has been accepted by the CDE.

For Boan Biotech progress:

In January 2021, all subjects under the phase I clinical trial in China for LY-CovMab completed enrolment with LY-CovMab. LY-CovMab is an innovative biological antibody product indicated for COVID-19, developed by Boan Biotech. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is the virus that causes COVID-19. LY-CovMab is a fully human monoclonal neutralizing antibody, which showed good effects for both therapeutic and prophylactic venues against SARS-CoV-2 infection. In May 2021, LY-CovMab completed phase I clinical trial in China. The results show that LY-CovMab has a good safety and tolerability profile. It provides a clear reference for later clinical trials. In June 2021, Boan Biotech has submitted the IND application for its new drug LY-CovMab to the FDA of the U.S.. This submission in the U.S. is in relation to a phase II clinical study evaluating the efficacy, safety, tolerability, pharmacokinetics and immunogenicity of LY-CovMab injection in patients with mild to moderate COVID-19. It is expected that Phase II clinical trial in relation to the drug will be carried out in multiple countries around the world.

In January 2021, the last dosing for all subjects in phase III clinical of Boan Biotech's recombinant anti-RANKL fully human monoclonal antibody injection (Denosumab injection, Prolia® biosimilar, "LY06006") in China has been completed. In the meanwhile, the Denosumab Injections (Prolia® biosimilar, LY06006/Xgeva® biosimilar, LY01011) are undergoing phase I clinical trials in Europe.

In February 2021, the recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection (Aflibercept intraocular injection solution, Eylea® biosimilar, "LY09004") of Boan Biotech completed the first patient dosing in phase III clinical trial in China.

In February 2021, the clinical trial application of Nivolumab injection ("LY01015") of Boan Biotech has been formally accepted by the CDE in China. LY01015 is the first applied biosimilar to OPDIVO® according to Registration Classification 3.3 of Biological Product. In May 2021, LY01015 has obtained the approval from the NMPA to initiate clinical trials.

In May 2021, the marketing registration in relation to the Bevacizumab injection ("LY01008", Boyounuo) product of Boan Biotech has been approved by the NMPA for the treatment of advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer. It is the first antibody drug developed by Boan Biotech which received marketing approval. In July 2021, LY01008 has been approved by the NMPA for the treatment of recurrent glioblastoma.

## SALES, MARKETING AND DISTRIBUTION

For global market:

The business of the Group covers 80 countries or regions including the U.S., countries in the European Union (EU), Japan, Association of Southeast Asian Nations ("ASEAN"), Latin America, Gulf Cooperation Council ("GCC") region and other emerging countries or regions. The Group also has strong sales partnerships with more than 50 partners throughout the world.

# MANAGEMENT DISCUSSION AND ANALYSIS

In March 2021, the Group has granted Italfarmaco Group (“Italfarmaco”) the exclusive rights to commercialize Rivastigmine MD in Germany, Italy, Portugal and Greece. Italfarmaco will also have a preferential right to market Rivastigmine MD in Chile and Vietnam. Italfarmaco is required to make an upfront payment to the Group upon the signing of the relevant agreement as well as additional payments when certain sales milestones are achieved. The Group is also eligible to receive royalties from Italfarmaco.

In August 2021, the Group has entered into an agreement with Zuellig Pharma, a leading healthcare service group in Asia, under which the Company grants Zuellig Pharma exclusive rights to distribute Seroquel (quetiapine fumarate, immediate release) and Seroquel XR (extended release formulation) in Malaysia and Brunei.

For China market:

The Group has established an extensive nationwide sales and distribution network and sold its products to 30 provinces, autonomous regions and municipalities throughout the PRC in the first half of 2021. The Group’s sales, marketing and distribution functions are conducted through around 1,000 sales and marketing personnel, a network of approximately 1,850 distributors that collectively enabled the Group to sell its products to over 18,800 hospitals, which comprised approximately 2,200 or approximately 87.0% of all Class III hospitals, approximately 5,500 or approximately 64.0% of all Class II hospitals and approximately 11,000 or approximately 57.0% of all Class I and other hospitals and medical institutions, in the PRC in the first half of 2021. The Group believes that its sales and marketing model and extensive coverage of hospitals with other medical institutions represent a significant competitive advantage and a culmination of both academic promotions by the Group’s in-house personnel in different regions and partnerships with high-quality distributors across China. The Group also believes that its sales and marketing model provides a solid foundation for the Group to continue to enhance market awareness of its brand and expand the market reach of its products.

In December 2020, Lipusu<sup>®</sup>, being the Group’s paclitaxel formulation with innovative liposome delivery system, has been included in the category B of the new Catalogue of NRDL. All indication of Lipusu<sup>®</sup>, including non-small cell lungs Cancer, ovarian and breast cancer, are reimbursed under the NRDL. The 2020 NRDL has come into effect in March 2021.

In May 2021, Boan Biotech granted AstraZeneca the exclusive promotion rights in relation to Boyounuo (“LY01008”, Bevacizumab injection) in the county markets of 21 provinces, cities and autonomous regions in the Mainland China. Under the abovementioned partnership, Boan Biotech and AstraZeneca will work closely together, playing to the strengths of each other, to consolidate and expand the business and market coverage of Boyounuo and enable more patients to benefit from the drug in China.

## BUSINESS COLLABORATIONS

In February 2021, the Group granted Towa Pharmaceutical Co., Ltd. (“Towa”) the exclusive right to develop and commercialize the new drug, Rivastigmine MD in Japan. Towa will make an upfront payment to the Group upon signing of the relevant agreement, and will make further milestone payments to the Group upon achievement of certain development, regulatory and sales milestones in relation to Rivastigmine MD. Towa will also make royalty payments on the sales Rivastigmine MD to the Group. In addition, Rivastigmine MD, as a new drug, is expected to enter into phase III clinical trials in Japan and Towa will bear all costs and expenses related to clinical studies and registration purposes in Japan.

In March 2021, Boan Biotech has entered into a cooperation with Horizon Discovery using its CHOSOURCE CHO-K1 GS (“CHOSOURCE”) Knockout expression platform for development of products. CHOSOURCE has a successful track record in the discovery and development of biopharmaceuticals; from applications in transient expression during research and early development to the generation of stable cell lines for clinical and commercial cGMP production of biotherapeutics. These include traditional monoclonal antibodies as well as fusion proteins, novel multi-specific antibodies and complex molecular architectures and scaffolds.

# MANAGEMENT DISCUSSION AND ANALYSIS

As mentioned above, the Group has granted Italfarmaco Group the exclusive rights to commercialize Rivastigmine MD in Germany, Italy, Portugal and Greece in March 2021. Italfarmaco will also have a preferential right to market Rivastigmine MD in Chile and Vietnam. Boan Biotech has granted AstraZeneca the exclusive promotion rights of Boyounuo in the county markets of 21 provinces, cities and autonomous regions in the Mainland China in May 2021.

## MANUFACTURING

For the six months ended 30 June 2021, the Group has been working on establishing a global quality control and quality assurance system as well as information platform to ensure the successful integration of the Group's global manufacturing facility system. The manufacturing facility of LY01008 (Boyounuo) has successfully passed the inspection by the NMPA. The manufacturing site for transdermal patches in Miesbach, Germany, maintained full capacity and met all customer demands in 2020 despite the COVID-19 related constraints on supply chain & logistics in many countries around where customers or suppliers reside. Customer audits during the year of 2020 were performed partly remotely and underlined the compliance with GMP standard.

## INDUSTRY POLICY RISK

### Volume-based Procurement ("VBP")

In the past two years, Chinese medical insurance policy had undergone substantial changes. The National Healthcare Security Administration ("NHSA") of China has organised several rounds of VBP. In the round of "4+7" VBP, 25 drugs won the bid with an average price cut of 51.0%. In the first round of national VBP in the "Alliance area", the 25 products cut price 24.0% on average compared with the first round of "4+7" VBP. While in the second round of national VBP in 31 provinces and cities in January 2020, another 32 drugs won the bid with an average price cut of 55.0%.

The Group's major product Bei Xi was included in the second round of national VBP with a price cut of approximately 60.0%. Even if the sales volume will significantly increase, there would still be an uncertainty in relation to its sales value growth.

In the third round of national VBP organised in August 2020, there are 56 products on the procurement list. Quetiapine fumarate, immediate release was included in the list and the Group's product Seroquel, as the originator, did not win the bidding. Three generic products won the bidding with a price cut of approximately 60.0%.

In the fourth round of national VBP in February 2021, there are 45 products on the procurement list. Quetiapine extended release formulation was included in the list and the Group's product Seroquel XR, as the originator, did not win the bidding. Three generic products won the bidding with a price cut of approximately 60.0%.

In the fifth round of national VBP in February 2021, there are 62 products on the procurement list. The Group's products were not included in this round of procurement.

With the further advancement of medical reform, VBP will become the core task of NHSA. It is generally believed that the drug VBP is expected to be fully implemented and become the standard practice in China.

### National Reimbursement Drug List Adjustment

For the NRDL, a yearly dynamic adjustment has become the new normal. Hundreds of exclusive products have been included in the NRDL by the negotiation with NHSA in the past two years. In 2019, exclusive products successfully included in the NRDL by the negotiation had an average price cut of 60.7%. In 2020, exclusive products successfully included in the NRDL by the negotiation had an average price cut of 50.6%.

## OUTLOOK

The Group's business was influenced by the Chinese medical insurance policy, market factors as well as the pandemic of COVID-19, it recorded a decrease in revenue of 0.4%.

Since it is a highly competitive industry, inevitably all the pharmaceutical companies are facing intense competition from other market participants. Furthermore, the industry is highly constrained by the government policy, which may cause great uncertainty during the pharmaceutical companies' developments. In recent years, policies such as VBP and NRDL have been creating significant impacts to the industry.

However, the Group continued to introduce measures to enhance efficiency in key aspects of its operations. With respect to its sales and marketing activities, the Group will continue to undertake a series of changes and initiatives to enable it to focus its marketing and promotion resources on the regions and products where marketing and promotion expenditure yields higher returns, thereby increasing its overall sales efficiency. The Group also intends to increase its profitability through production efficiency. In addition, the Group intends to further strengthen its R&D capabilities and develop its pipeline product candidates.

In December 2020, Lipusu<sup>®</sup>, being the Group's paclitaxel formulation with innovative liposome delivery system, has been included in the category B of the new Catalogue of NRDL. All indications of Lipusu<sup>®</sup>, including non-small cell lung cancer, ovarian and breast cancer, are reimbursed under the NRDL. The inclusion of Lipusu<sup>®</sup> in the NRDL demonstrates that NHA recognizes, among other factors, the clinical value, patients benefit and novelty of Lipusu<sup>®</sup>. This will also allow more patients to be able to afford Lipusu<sup>®</sup>, increase its penetration into the relevant indications, and provide momentum to its long-term growth.

The Group also put a lot of effort on the academic studies of the marketed products. The Group's major product Lipusu has been recommended under the Chinese Society of Clinical Oncology (中國臨床腫瘤學會) guidelines (the "Guidelines") on diagnosis and treatment of breast cancer for first-line rescue chemotherapy for Her2-negative advanced breast cancer and also as a first-line drug on diagnosis and treatment of primary lung cancer. The Group believes that the inclusion of Lipusu in the Guidelines represents a high recognition of its clinical value, which will significantly increase its penetration into the relevant indications.

In January 2021, the marketing registration of Risperidone Microspheres for Injection (II) ("LY03004", Rykindo<sup>®</sup>) was approved by the NMPA. It was the first innovative formulation developed under the Group's long acting and extended technology platform that received marketing approval. Rykindo<sup>®</sup>/LY03004 is an extended-release microspheres for injection administered bi-weekly for the treatment of schizophrenia.

Compared to orally administered antipsychotics, long-acting formulations do not require daily administration, and are thus better received by patients and could lower the sense of self-stigmatization associated with their diseases. Patients are also less likely to skip drug administration, and face a lower risk of drug overdose with long-acting drugs. Patients using long-acting injectables have steady plasma drug levels and will not suffer an immediate relapse when drugs are not administered in a timely manner due to a slower drop of plasma drug level. Rykindo<sup>®</sup> can significantly improve the medication compliance issues which are common among patients with schizophrenia in relation to oral antipsychotic drugs, and simplify the treatment regimen.

## MANAGEMENT DISCUSSION AND ANALYSIS

Rykindo<sup>®</sup> also has several advantages over another marketed long-acting injectable drug. For example, unlike the reference drug, there is no need for administration of the oral formulation following the first injection of Rykindo<sup>®</sup>. Furthermore, steady plasma drug levels can be reached much faster with Rykindo<sup>®</sup> than with the reference product. Thus, patients at acute phase who are less compliant and cooperative can benefit from the fast symptom control afforded by Rykindo<sup>®</sup>. After the discontinuation of use, the concentration of Rykindo<sup>®</sup> in human body drops markedly faster than that of the reference drug, making it convenient for doctors to adjust dosage according to patients' conditions. Patients using Rykindo<sup>®</sup> also have stable clinically effective plasma drug level and can benefit from more convenient clinical treatment as a result.

In May 2021, the marketing registration in relation to the Bevacizumab injection (LY01008, Boyounuo) product of Boan Biotech has been approved by the NMPA for the treatment of advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer. It is the first antibody drug developed by Boan Biotech which received marketing approval. In July 2021, LY01008 has been approved by the NMPA for the treatment of recurrent glioblastoma.

Boyounuo is an anti-VEGF humanized monoclonal antibody injection and a biosimilar to Avastin<sup>®</sup> independently developed by Boan Biotech. Avastin<sup>®</sup> has been approved worldwide for the treatment of non-small cell lung cancer, metastatic colorectal cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer and other solid tumors. Its significant efficacy and well safety have been widely recognized. According to the "Guidelines on Similarity Evaluation and Indication Extrapolation of Biosimilars" (《生物類似藥相似性評價和適應症外推技術指導原則》), Boyounuo can be gradually applied and approved for all indications of Avastin<sup>®</sup> approved in China. According to the data from IQVIA, global sales of Bevacizumab injection were US\$6.09 billion, and sales in China were RMB3.63 billion in 2020.

In May 2021, Rivastigmine MD is eligible for marketing authorization by individual member states in the European Union.

Rivastigmine MD is a twice-weekly innovative patch formulation of Rivastigmine for the treatment of mild to moderate dementia associated with Alzheimer's disease. The product was developed by the Group on its proprietary transdermal patch platform and is one of the Group's core products in the CNS therapeutic field.

Rivastigmine is in a class of medicines called cholinesterase inhibitors. Such medicines can improve cognitive functions, such as memory and thinking, by increasing the amount of a certain natural substance in the brain and amplifying the communication channels between nerve cells, which are less active in individuals with mild to moderate Alzheimer's disease. The drug is currently available in the form of tablets and patches.

Rivastigmine MD requires lower frequency of application than the Rivastigmine once-daily patches generally available in the market, enabling it to improve patients' medication adherence. Due to its transdermal route of administration, Rivastigmine MD is convenient for patients who have difficulty in swallowing, and it might have the potential to lower the incidence of gastrointestinal adverse reactions such as nausea and vomiting compared with the oral form. The Group has filed, and been issued, a portfolio of international patents protecting Rivastigmine MD.

In addition to Rykindo<sup>®</sup>, Boyounuo and Rivastigmine MD during the six months ended 30 June 2021, the Group has made remarkable progresses in R&D fields. In China, the marketing authorization application of LY03005 has been accepted by the CDE; LY06006 completed the last dosing for all subjects in phase III clinical trial; LY09004 completed the first patient dosing in phase III clinical trial; LY-CovMab completed phase I clinical trial; LY03014 commenced enrolment of subjects in phase I clinical trial; the clinical trial application of LY01015, LY09606 has been approved by the CDE. Internationally, LY-CovMab has submitted the IND application for phase II clinical trial in the U.S.; LY03003 completed phase I clinical trial in Japan; LY03009 commenced phase I clinical trial in Australia; LY03015 has submitted the IND application in the U.S..

# MANAGEMENT DISCUSSION AND ANALYSIS

For sales and distribution of oncology products, with the Lipusu<sup>®</sup> included in the NRDL, the Group will deepen the penetration of market coverage into lower-tier hospitals. Boan Biotech has also established a sales & marketing team to commercialize Boyounuo in main market of China. In the meanwhile, Boan Biotech granted AstraZeneca the exclusive promotion rights of Boyounuo in the county markets of 21 provinces, cities and autonomous regions in China in May 2021. Boan Biotech and AstraZeneca will work closely together, playing to the strengths of each other, to consolidate and expand the business and market coverage of Boyounuo and enable more patients to benefit from the drug in China.

For sales and distribution of CNS products, the Group has built a CNS sales team of over 110 representatives. With the market synergy of Seroquel and Seroquel XR, the two products (Rykindo<sup>®</sup> and Rivastigmine MD) approved to be marketed in China will become the Group's new growth points. For global markets, the Group will continuously search regional partners. The Group's Rivastigmine MD has been approved in EU market, it will contribute to the growth of the Group's global sales.

Additionally, Boan Biotech has developed more than 10 innovative antibody products with international intellectual property protection and eight biosimilar products. Its diversified products will also contribute to the long term growth of the Group.

Looking forward to the whole year, significant changes have taken place for the macro-economic environment. The outbreak of COVID-19, the global economic fluctuations and policy changes have brought new challenges to the daily operation of the industry. Facing these challenges, the Group needs to further improve the management efficiency and put more efforts to the R&D of key products, speeding up the launch of the pipeline product candidates. Externally, the Group will keep penetrating into the domestic and international markets with advantages, widely seeking outside cooperation opportunities to ensure the business maintains high-quality and healthy growth.

## FINANCIAL REVIEW

### Revenue

For the six months ended 30 June 2021, the Group's revenue amounted to approximately RMB2,951.7 million, as compared to RMB2,962.2 million for the six months ended 30 June 2020, representing a decrease of approximately RMB10.5 million, or 0.4%. The amount included sales of product know-how which comprised approximately 16.3% of total revenue. The decrease was mainly attributable to decrease in sales of some of the Group's key products.

For the six months ended 30 June 2021, revenue from sales of oncology products decreased to RMB927.0 million, as compared to RMB1,334.2 million for the six months ended 30 June 2020, representing a decrease of approximately RMB407.2 million, or 30.5%, primarily attributable to the decrease in average selling price of the key oncology product of the Group.

For the six months ended 30 June 2021, revenue from sales of cardiovascular system products increased to RMB800.7 million, as compared to RMB429.5 million for the six months ended 30 June 2020, representing an increase of approximately RMB371.2 million, or 86.4%, primarily attributable to the increase in sales volume of a few cardiovascular system products of the Group.

For the six months ended 30 June 2021, revenue from sales of alimentary tract and metabolism products increased to RMB458.3 million, as compared to RMB391.3 million for the six months ended 30 June 2020, representing an increase of approximately RMB67.0 million, or 17.1%, primarily attributable to the increase in the sales volume of some alimentary tract and metabolism products of the Group.

# MANAGEMENT DISCUSSION AND ANALYSIS

For the six months ended 30 June 2021, revenue from sales of CNS products decreased to RMB694.4 million, as compared to RMB746.3 million for the six months ended 30 June 2020, representing a decrease of approximately RMB51.9 million or 7.0%, primarily attributable to the decrease in sales of CNS products.

For the six months ended 30 June 2021, revenue from sales of other products increased to RMB71.3 million, as compared to RMB60.8 million for the six months ended 30 June 2020, representing an increase of approximately RMB10.5 million, or 17.3%, primarily attributable to the increase in sales volume of various other products of the Group.

## Cost of Sales

The Group's cost of sales increased from RMB764.3 million for the six months ended 30 June 2020 to approximately RMB998.0 million for the six months ended 30 June 2021, which accounted for approximately 33.8% of the Group's total revenue for the same period.

## Gross Profit

For the six months ended 30 June 2021, the Group's gross profit decreased to RMB1,953.7 million, as compared to RMB2,197.9 million for the six months ended 30 June 2020, representing a decrease of approximately RMB244.2 million, or 11.1%. The gross profit margin of 66.2%, which decreased slightly as compared to 74.2% for the six months ended 30 June 2020 mainly due to the drop in selling price of some products and higher sales of slightly lower margin products.

## Other Income and Gains

The Group's other income and gains mainly comprised of government grants, interest income and investment income. For the six months ended 30 June 2021, the Group's other income and gains decreased to RMB162.3 million, as compared to RMB181.6 million for the six months ended 30 June 2020, representing a decrease of approximately RMB19.3 million, or 10.6%. The decrease was mainly attributable to decrease in government grants recognised during the period.

## Selling and Distribution Expenses

The Group's selling and distribution expenses consisted of expenses that were directly related to the Group's marketing, promotion and distribution activities. For the six months ended 30 June 2021, the Group's selling and distribution expenses amounted to RMB770.7 million, as compared to RMB873.9 million for the six months ended 30 June 2020, representing a decrease of RMB103.2 million, or 11.8%. The decrease was mainly attributable to decrease in promotion expenses and conference expenses. On the other hand, as a percentage of revenue, the Group's selling and distribution expenses decreased from 29.5% for the six months ended 30 June 2020 to 26.1% for the six months ended 30 June 2021, primarily as a result of the lower selling and distribution expense margin and higher sales of lower expense product.

## Administrative Expenses

The Group's administrative expenses primarily consisted of staff cost, general operating expenses, conference and entertainment expenses, travel and transportation expenses, depreciation, amortisation and impairment loss, auditor's remuneration, consulting expenses, bank charges, taxation and other administrative expenses. For the six months ended 30 June 2021, the Group's administrative expenses amounted to approximately RMB281.9 million, as compared to RMB248.0 million for the six months ended 30 June 2020, representing an increase of approximately RMB33.9 million, or 13.7%. The increase was primarily attributable to higher staff cost and taxation during the period.

# MANAGEMENT DISCUSSION AND ANALYSIS

## Other Expenses

The Group's other expenses primarily consisted of its R&D costs, changes in fair value of financial instruments, donations, loss on disposals of property, plant and equipment and miscellaneous expenses. For the six months ended 30 June 2021, the Group's other expenses amounted to approximately RMB379.3 million, as compared to RMB351.0 million for the six months ended 30 June 2020, representing an increase of approximately RMB28.3 million, or 8.1%. The increase was mainly due to a fair value adjustment on contingent considerations and fair value adjustment on redemption liabilities during the period.

## Finance Costs

For the six months ended 30 June 2021, the Group's finance costs amounted to RMB196.0 million, as compared to RMB223.0 million for the six months ended 30 June 2020, representing a decrease of approximately RMB27.0 million, or 12.1%. The decrease was mainly due to lower level of monthly average outstanding bank borrowings and convertible bonds interests during the six months ended 30 June 2021 as compared to the corresponding period of 2020.

## Income Tax Expense

For the six months ended 30 June 2021, the Group's income tax expense amounted to RMB80.4 million, as compared to RMB144.2 million for the six months ended 30 June 2020, representing a decrease of RMB63.8 million, or 44.2%. The effective tax rates for the six months ended 30 June 2021 and 2020 were 16.5% and 21.1%, respectively.

## Net Profit

The Group's net profit for the six months ended 30 June 2021 was approximately RMB408.0 million, as compared to RMB540.3 million for the six months ended 30 June 2020, representing a decrease of approximately RMB132.3 million, or 24.5%.

## LIQUIDITY, FINANCIAL AND CAPITAL RESOURCES

During the six months ended 30 June 2021, the Group funded its working capital requirements principally from cash generated from operations and bank borrowings. The Company used the entire proceeds from the issue of new shares to repay loans of the Group. For further details, see "Use of Proceeds of Issue of New Shares" below. As at 30 June 2021, the Group's cash and cash equivalents was at RMB4,943.6 million, increased by 27.9% compared to RMB3,865.4 million as at 31 December 2020.

As at 30 June 2021, the Group had net current assets of approximately RMB4,562.1 million, as compared to approximately RMB2,736.3 million as at 31 December 2020. The current ratio of the Group increased slightly to approximately 1.7 as at 30 June 2021 from approximately 1.4 as at 31 December 2020. The increase in net current assets was mainly attributable to lower level of loans and borrowings in current liability.

## Funding and Treasury Policies

The Group's funding and treasury policy is responsible and handled by our Group's finance and treasury department. The Group has always been maintaining a prudent approach on our funding and treasury policy and the policy will be reviewed on a timely basis to ensure its effectiveness. The Group's working capital and other capital requirements are normally funded from a combination of various sources such as operating cash flow and external financing. To sustain the Group's ability to continue as a going concern, the Group has implemented monthly and yearly cash flow projection report which is reviewed weekly to maintain its accuracy. Most of the Group's cash and cash equivalents and financial assets are held in major and reputable financial institutions in Mainland China and overseas. Borrowings are mainly with major financial institutions and at reasonable market rates.

## Borrowings and Pledge of Assets

As at 30 June 2021, the Group had an aggregate interest-bearing loans and borrowings of approximately RMB7,063.6 million, as compared to approximately RMB8,170.6 million as at 31 December 2020. Amongst the loans and borrowings, approximately RMB4,662.2 million are repayable within one year, and approximately RMB2,401.4 million are repayable after one year. RMB3,775.5 million of the loans and borrowings of the Group carried interest at fixed interest rate. The increase in loans and borrowings is mainly for working capital of the Group. The bank loans were secured by the Group's time deposits, property, plant and equipment, other unlisted investments and notes receivable. As at 30 June 2021, the Group's borrowings were primarily denominated in RMB, Euro and U.S. dollars, and the cash and cash equivalents were primarily denominated in RMB, Euro and U.S. dollars.

## Gearing Ratio

As at 30 June 2021, the gearing ratio of the Group, which is calculated by dividing total borrowings by total equity, decreased to 72.8% from 100.9% as at 31 December 2020. The decrease was primarily due to a decrease in the Group's total borrowings taken during the reporting period.

## Contingent Liabilities

As at the date of this report, a subsidiary of the Group, was involved in arbitration proceedings commenced by the previous distributor of Seroquel in Mainland China disputing the subsidiary's basis of terminating the distribution agreement with such distributor. The Directors, based on information currently available to the Group and preliminary assessment taking into account the advice from the Group's relevant legal counsel in relation to the arbitration proceedings, believe that the subsidiary has a valid defence against the allegation and, accordingly, have not provided for any claim arising from the arbitration, other than for the related legal and other costs.

## Foreign Exchange and Exchange Rate Risk

The Group primarily operates in the PRC and is exposed to foreign currency risk arising from fluctuations in exchange rate between RMB and other currencies in which the Group conducts its business. The Group is subject to foreign currency risk attributable to the bank balances, trade and other receivables and payables as well as bank loans that are denominated in currencies other than RMB. The Group seeks to limit the exposure to foreign currency risk by minimising its net foreign currency position. The Group did not enter into any hedging transactions in respect of foreign currency risk as at 30 June 2021. The Directors expect that the fluctuation of the RMB exchange rate will not have a material adverse effect on the operation of the Group.

## Issuance of Convertible Bonds

On 9 July 2019, the Company issued 1.50 per cent convertible bonds with an aggregate principal amount of US\$300,000,000. There was no movement in the number of these convertible bonds during the period. The bonds are convertible at the option of the bondholders into ordinary shares with the initial conversion price of HK\$8.15 per share at any time on or after 19 August 2019 and up to the close of business on the date falling ten days prior to 9 July 2024. The bonds are redeemable at the option of the bondholders at a 3.75 per cent gross yield upon early redemption. Any convertible bonds not converted will be redeemed on 9 July 2024 at 112.25 per cent of its principal amount together with accrued but unpaid interest thereon. The bonds carry interest at a rate of 1.50 per cent per annum, which is payable semiannually in arrears on 9 January and 9 July. For further details, please refer to the announcements of the Company dated 24 June 2019 and 9 July 2019, and the announcements on adjustment to conversion price dated 5 September 2019 and 29 June 2020.

The net proceeds from the bonds (after deduction of commissions and other related expenses) are approximately US\$296,430,000. The Group intends to apply the net proceeds from the issue of the bonds for refinancing the Group's indebtedness and general corporate purposes. As of 30 June 2021, all of the net proceeds of the bonds were allocated or applied to repay loans and other general corporate purposes.

# MANAGEMENT DISCUSSION AND ANALYSIS

The initial conversion price of the bonds was HK\$8.15 per share and was adjusted to HK\$7.90 per share with effect from 3 July 2020, as disclosed in the announcement dated 29 June 2020. Assuming full conversion of the bonds at the adjusted conversion price, the total number of shares issued by the Company would be 296,760,759 shares.

## Use of Proceeds of Issue of New Shares

On 29 January 2021, the Company and Hillhouse NEV Holdings Limited (“Hillhouse NEV”, a company formed under the laws of British Virgin Islands to which Hillhouse Capital Management, Ltd., a global firm of investment professionals and operating executives focused on building and investing in high quality business franchises that achieve sustainable growth, is the sole investment manager) entered into the subscription agreement, pursuant to which Hillhouse NEV subscribed for 292,406,881 new ordinary shares (par value: US\$0.02; aggregate nominal value: US\$5,848,137.62) issued by the Company, representing approximately 8.26% of the issued share capital of the Company as enlarged by the issue of such new shares. The subscription price was HK\$4.28 per share. The subscription price represents a premium of approximately 10.03% over the closing price of HK\$3.89 per share as quoted on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) on 29 January 2021, being the date of the subscription agreement. For further details, please refer to the announcements of the Company dated 31 January 2021 and 8 February 2021.

The net proceeds from the issue of new shares are approximately RMB1,044,477,000 (approximately US\$161,411,163; net price per issued share: approximately RMB3.57). The Group’s plan was to apply such net proceeds to refinance the Group’s indebtedness and for general corporate purposes. As of 30 June 2021, the entire amount of the net proceeds had been allocated or applied to repay loans of the Group.

The subscription and issue represent an opportunity to raise capital for the Company while having Hillhouse NEV as a strategic investor will strengthen the Company’s shareholder base. Further, the subscription and issue would strengthen the financial position of the Group and provide working capital to the Group.

## Share Award Scheme (the “Scheme”)

The Company adopted the Scheme on 10 January 2017. The purpose of the Scheme is to recognise contributions by certain employees, including any executive director of any member of the Group except for the current executive directors and to provide them with incentives in order to retain them for the continuing operation and development of the Group and to attract suitable personnel for the further development of the Group. As at 30 June 2021, the Board has not granted any share to employees (2020: Nil) under the Scheme. For further details on the Scheme, please refer to note 23 to the interim condensed consolidated financial information.

## Hedging Activities

As at 30 June 2021, the Group did not use any financial instruments for hedging purposes and did not enter into any hedging transactions in respect of foreign currency risk or interest rate risk.

## SIGNIFICANT INVESTMENTS HELD

As at 30 June 2021, the Group did not have any significant investments.

## FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

The Group does not have other plans for material investments or capital assets.

## EMPLOYEES AND REMUNERATION POLICY

As at 30 June 2021, the Group employed a total of 4,788 employees, as compared to a total of 4,963 employees as at 31 December 2020. The staff costs (including Directors' emoluments but excluding any contributions to pension scheme) were approximately RMB467.4 million for the six months ended 30 June 2021 as compared to RMB405.3 million for the corresponding period in 2020. The objective of the Group's remuneration policy is to motivate and retain talented employees to achieve the Group's long-term corporate goals and objectives. The Group's employee remuneration policy is determined by taking into account factors such as remuneration in respect of the overall remuneration standard in the industry and employee's performance. The management reviews the Group's employee remuneration policy and arrangements on a regular basis. Moreover, the social insurance contributions are made by the Group for its PRC employees in accordance with the relevant PRC regulations.

## PENSION SCHEMES

The following provides supplemental information on the pension schemes of the Group as disclosed in the annual report of the Company for the year ended 31 December 2020.

### Pension Schemes in the PRC and Singapore

As disclosed in note 2.4 to the financial statements of the Group for the year ended 31 December 2020 contained in the 2020 Annual Report, the Group participates in the national pension schemes as defined by the laws of the countries in which it has operations. The Group makes contributions to the Central Provident Fund (the "CPF") Scheme in Singapore, a defined contribution pension scheme, for its employees in Singapore. Further, members of the Group established and operate in Mainland China are required to provide certain staff pension benefits to their employees under existing regulations of the PRC (the "PRC Pension Scheme"). The Group's employer contributions to the CPF and the PRC Pension Scheme vest fully with the employees upon the contributions are made and hence no forfeited contributions arise when the employees leave the respective scheme.

### Defined Benefit Plan in Switzerland

As disclosed in note 40 ("Note 40") to the financial statements of the Group for the year ended 31 December 2020 contained in the 2020 Annual Report, the Group has a defined benefit pension plan in Switzerland, which was adopted by Luye Supply AG. Note 40 contains the actuarial valuation of the pension liabilities of the Group under such plan as at 31 December 2020, as extracted from the report dated 12 January 2021 prepared by Prevanto AG, who are accredited pension actuaries in Switzerland. The valuation was determined based on the projected unit credit method and the principal assumptions used in determining the Group's benefit obligations under the plan are set out in Note 40.

## SUBSEQUENT EVENTS AFTER THE REPORTING PERIOD

The Group did not have any significant subsequent events after the interim period ended 30 June 2021.

## **LOAN AGREEMENT WITH COVENANTS RELATING TO SPECIFIC PERFORMANCE OBLIGATIONS OF THE CONTROLLING SHAREHOLDER**

As disclosed in the announcement of the Company dated 2 August 2018, pursuant to the term of the facility agreement dated 2 August 2018 (“August Facility Agreement”) entered into between Luye Pharma Europe AG (formerly known as Luye Pharma Switzerland AG) (“LPEU”) and a bank (the “Bank”), the Bank has agreed to grant to LPEU a term loan facility of up to EUR120 million for a term of 60 months from the date of initial utilisation under the August Facility Agreement. Under the August Facility Agreement, in the event that Luye Pharmaceutical Investment Co., Ltd. ceases to be (i) the actual controller; or (ii) the first majority/single largest shareholder of the Company, all or any part of the commitments under the August Facility Agreement may be cancelled and all amounts outstanding under the August Facility Agreement may become immediately due and payable.

## **LEGAL PROCEEDINGS**

A subsidiary of the Group is currently involved in an arbitration brought by the former distributor of Seroquel in Mainland China disputing the subsidiary’s basis of terminating the distribution agreement with such distributor. The Directors, based on information currently available to the Group and preliminary assessment taking into account the advice from the Group’s legal counsel in relation to the arbitration proceedings, believe that the subsidiary has a valid defence against the allegation and, accordingly, have not provided for any claim arising from the litigation, other than the related legal and other costs.

# OTHER INFORMATION

## INTERIM DIVIDEND

No interim dividend was proposed by the Board for the six months ended 30 June 2021 (the six months ended 30 June 2020: Nil per share).

## CORPORATE GOVERNANCE PRACTICES

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of shareholders and to enhance corporate value and accountability. The Company has adopted the Corporate Governance Code (the “CG Code”) contained in Appendix 14 to the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”) as its own code of corporate governance.

During the six months ended 30 June 2021, the Company has complied with all the applicable code provisions set out in the CG Code, save and except for the deviation from Code provision A.2.1 of the CG Code, which requires the roles of chairman and chief executive officer should be separate and performed by different individuals.

Under the current organisation structure of the Company, Mr. Liu Dian Bo is the Executive Chairman of the Board and the Chief Executive Officer. With extensive experience in the pharmaceutical industry, the Board considers that vesting the roles of chairman and chief executive officer in the same person is beneficial to the business prospects and management of the Group. The balance of power and authority is ensured by the operation of the senior management and the Board, which comprise experienced and high-caliber individuals.

## MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted a code of conduct regarding Directors’ securities transactions on terms no less exacting than the required standard set out in the Model Code for Securities Transactions by Directors of Listed Issuer (the “Model Code”) of Appendix 10 to the Listing Rules. Specific enquiry has been made of all the Directors and the Directors have confirmed that they have complied with the Model Code during the six months ended 30 June 2021.

## PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

On 8 February 2021, the Company allotted and issued 292,406,881 new shares of the Company at HK\$4.28 per share in cash to Hillhouse NEV Holdings Limited pursuant to the subscription agreement dated 29 January 2021.

Save as disclosed above, there was no purchase, sale or redemption by of the Company or any of its subsidiaries of any listed securities of the Company for the six months ended 30 June 2021.

## AUDIT COMMITTEE

The Audit Committee of the Company has reviewed, with the management, the accounting principles and policies adopted by the Group, and discussed the unaudited interim condensed consolidated financial statements and interim results announcement of the Group for the six months ended 30 June 2021 and recommended its adoption by the Board.

## OTHER INFORMATION

In addition, the independent auditor of the Company, Ernst & Young, has reviewed the unaudited interim results for the six months ended 30 June 2021 in accordance with Hong Kong Standard on Review Engagements 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Hong Kong Institute of Certified Public Accountants.

## CHANGES IN DIRECTORS’ INFORMATION

Pursuant to Rule 13.51B(1) of the Listing Rules, the changes in directors’ information since the date of the Company’s annual report for the year ended 31 December 2020, are set out as follows:

- Mr. SUN Xin has been appointed as a non-executive director of the Company with effect from 8 February 2021.
- Mr. ZHANG Hua Qiao has retired from his position as independent non-executive director of China Huirong Financial Holdings Limited (a company listed on the Stock Exchange (stock code: 1290)) in May 2021 and has been serving as an independent non-executive director of Haitong International Securities Group Limited (a company listed on the Stock Exchange (stock code: 0665)) since May 2021.
- Professor LO Yuk Lam has been serving as an independent non-executive director of Zhaoke Ophthalmology Limited (a company listed on the Stock Exchange (stock code: 6622)) since April 2021.

Other than disclosed above, the Company is not aware of other changes in respect of the directors of the Company which are required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

## DIRECTORS’ RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as otherwise disclosed in this interim report, no rights to acquire benefits by means of the acquisition of shares in or debentures of the Company were granted to any Director or their respective spouse or children under 18 years of age, or were any such rights exercised by them; or was the Company and any of its subsidiaries a party to any arrangement to enable the Directors, or their respective spouse or children under 18 years of age, to acquire such rights in any other body corporate for the six months ended 30 June 2021.

### SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 30 June 2021, to the best of the Directors' knowledge, the following persons (other than the Directors and chief executives of the Company) had or were deemed or taken to have an interests and/or short position in the shares or the underlying shares which fall to be disclosed under the provisions of Divisions 2 and 3 of Part XV of the SFO or as recorded in the register required to be kept pursuant to Section 336 of the SFO:

Name	Capacity/Nature of interest	Number of securities <sup>(1)</sup>	Approximate percentage of shareholding
LuYe Pharmaceutical Investment Co., Ltd. <sup>(1)</sup>	Beneficial owner	1,257,196,703(L)	35.50%
		72,701,950(S)	2.05%
LuYe Pharmaceutical International Co., Ltd. <sup>(1)</sup>	Interest in controlled corporation	1,257,196,703(L)	35.50%
		72,701,950(S)	2.05%
Luye Pharma Holdings Ltd. <sup>(1)</sup>	Interest in controlled corporation	1,257,196,703(L)	35.50%
		72,701,950(S)	2.05%
Luye Life Sciences Group Ltd. <sup>(2)</sup>	Interest in controlled corporation	1,257,196,703(L)	35.50%
		72,701,950(S)	2.05%
Nelumbo Investments Limited <sup>(2)</sup>	Interest in controlled corporation	1,257,196,703(L)	35.50%
		72,701,950(S)	2.05%
Ginkgo (PTC) Limited <sup>(2)</sup>	Trustee	1,257,196,703(L)	35.50%
		72,701,950(S)	2.05%
Shorea LBG <sup>(2)</sup>	Interest in controlled corporation	1,257,196,703(L)	35.50%
		72,701,950(S)	2.05%
Hillhouse Capital Management, Ltd. <sup>(3)</sup>	Investment Manager	552,324,108(L)	15.60%
Hillhouse Fund V, L.P. <sup>(3)</sup>	Interest in controlled corporation	552,324,108(L)	15.60%
Hillhouse NEV Holdings Limited <sup>(3)</sup>	Beneficial Owner	552,324,108(L)	15.60%

Remark: The Letter "L" denotes long position in such securities and "S" denotes short position in such securities.

Notes:

- LuYe Pharmaceutical Investment Co., Ltd. is wholly-owned by LuYe Pharmaceutical International Co., Ltd., which is in turn wholly-owned by Luye Pharma Holdings Ltd..
- Nelumbo Investments Limited holds 70% of the issued share capital of Luye Life Sciences Group Ltd. The entire issued share capital of Nelumbo Investments Limited is held by Ginkgo (PTC) Limited as trustee of the family trust of Mr. Liu Dian Bo. Ginkgo (PTC) Limited is wholly-owned by Shorea LBG whose sole shareholder is Mr. Liu Dian Bo.
- Hillhouse NEV Holdings Limited is wholly-owned by Hillhouse Fund V, L.P. and Hillhouse Capital Management, Ltd. is the sole investment manager of Hillhouse NEV Holdings Limited.

Save as disclosed above, as at 30 June 2021, the Directors have not been aware of any person who had interests or short positions in the shares or underlying shares of the Company which would be required to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or as recorded in the register required to be kept pursuant to Section 336 of the SFO.

## OTHER INFORMATION

### DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITION IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 30 June 2021, the interests or short positions of the Directors or chief executive of the Company in the shares, underlying shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interest or short positions which they were taken or deemed to have under such provisions of the SFO), or which would be required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein, or which would be required to be notified to the Company and the Stock Exchange pursuant to the Model Code, are as follows:

#### (i) Interest in the Company

Name of Director	Nature of interest	Number of securities <sup>(1)</sup>	Approximate percentage of shareholding
Liu Dian Bo <sup>(1)(2)</sup>	Founder of a discretionary trust	1,257,196,703(L) 72,701,950(S)	35.50% 2.05%
Zhang Hua Qiao <sup>(3)</sup>	Beneficial owner	250,000(L)	0.01%
Lo Yuk Lam <sup>(3)</sup>	Beneficial owner	250,000(L)	0.01%
Leung Man Kit <sup>(3)</sup>	Beneficial owner	250,000(L)	0.01%
Choy Sze Chung Jojo <sup>(3)</sup>	Beneficial owner	250,000(L)	0.01%
Song Rui Lin <sup>(3)</sup>	Beneficial owner	250,000(L)	0.01%

Remark: The Letter "L" denotes long position in such securities and "S" denotes short position in such securities.

Notes:

1. Mr. Liu Dian Bo through his controlled corporations, namely Shorea LBG, Ginkgo (PTC) Limited, Nelumbo Investments Limited, Luye Life Sciences Group Ltd., Luye Pharma Holdings Ltd., LuYe Pharmaceutical International Co., Ltd. and LuYe Pharmaceutical Investment Co., Ltd., is deemed to be interested in 1,257,196,703 ordinary shares and 72,701,950 short position in the Company held by LuYe Pharmaceutical Investment Co., Ltd. Nelumbo Investments Limited holds 70% of the issued share capital of Luye Life Sciences Group Ltd.
2. The entire issued share capital of Nelumbo Investments Limited is held by Ginkgo (PTC) Limited as trustee of the family trust of Mr. Liu Dian Bo. Ginkgo (PTC) Limited is wholly-owned by Shorea LBG whose sole shareholder is Mr. Liu Dian Bo.
3. These represent the interests in underlying shares in respect of the awarded shares granted by the Company under Luye Pharma Share Award Scheme.

## OTHER INFORMATION

### (ii) Interest in associated corporations

Name of Director	Associated Corporation	Nature of interest	Number of securities	Approximate percentage in the registered capital of the associated corporation
Liu Dian Bo	Luye Life Sciences Group Ltd.	Founder of a discretionary trust	8,400(L)	70%
Liu Dian Bo	Ginkgo (PTC) Limited	Founder of a discretionary trust	1(L)	100%
Liu Dian Bo	Luye Pharma Holdings Ltd.	Founder of a discretionary trust	1,136,852(L)	100%
Liu Dian Bo	LuYe Pharmaceutical International Co., Ltd.	Founder of a discretionary trust	202,180,988(L)	100%
Liu Dian Bo	LuYe Pharmaceutical Investment Co., Ltd.	Founder of a discretionary trust	1(L)	100%
Liu Dian Bo	Nelumbo Investments Limited	Founder of a discretionary trust	1(L)	100%
Yang Rong Bing	Luye Life Sciences Group Ltd.	Beneficial interest	1,800(L)	15%
Yuan Hui Xian	Luye Life Sciences Group Ltd.	Beneficial interest	1,800(L)	15%

Remark: The Letter "L" denotes long position in such securities.

Notes:

1. The entire issued share capital of Nelumbo Investments Limited is held by Ginkgo (PTC) Limited as trustee of the family trust of Mr. Liu Dian Bo.
2. Luye Life Sciences Group Ltd. holds the entire issued ordinary share capital of Luye Pharma Holdings Ltd. LuYe Pharmaceutical International Co., Ltd. is wholly-owned by Luye Pharma Holdings Ltd. and LuYe Pharmaceutical Investment Co., Ltd. is wholly-owned by Luye Pharmaceutical International Co., Ltd.

Save as disclosed above, as at 30 June 2021, none of our Directors and chief executive of the Company has any interests or short positions in the shares, underlying shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which were (i) recorded in the register required to be kept under Section 352 of the SFO, or (ii) otherwise notified to the Company and the Stock Exchange pursuant to the Model Code.

# REVIEW REPORT OF INTERIM FINANCIAL INFORMATION



**Ernst & Young**  
27/F, One Taikoo Place  
979 King's Road  
Quarry Bay, Hong Kong

安永會計師事務所  
香港鰂魚涌英皇道979號  
太古坊一座27樓

Tel 電話: +852 2846 9888  
Fax 傳真: +852 2868 4432  
ey.com

## To the board of directors of Luye Pharma Group Ltd.

*(Incorporated in Bermuda with limited liability)*

## INTRODUCTION

We have reviewed the interim financial information set out on pages 28 to 70, which comprises the condensed consolidated statement of financial position of Luye Pharma Group Ltd. (the “Company”) and its subsidiaries (the “Group”) as at 30 June 2021 and the related condensed consolidated statements of profit or loss, comprehensive income, changes in equity and cash flows for the six-month period then ended, and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 *Interim Financial Reporting* (“IAS 34”) issued by the International Accounting Standards Board (“IASB”). The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with IAS 34. Our responsibility is to express a conclusion on this interim financial information based on our review. Our report is made solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

## SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Hong Kong Institute of Certified Public Accountants. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

## CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information is not prepared, in all material respects, in accordance with IAS 34.

**Ernst & Young**  
*Certified Public Accountants*  
Hong Kong  
27 August 2021

# INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended 30 June 2021

	Notes	30 June 2021 (Unaudited) RMB'000	30 June 2020 (Unaudited) RMB'000
<b>REVENUE</b>	4	2,951,664	2,962,201
Cost of sales		(997,983)	(764,336)
Gross profit		1,953,681	2,197,865
Other income and gains	4	162,288	181,568
Selling and distribution expenses		(770,728)	(873,863)
Administrative expenses		(281,873)	(248,018)
Other expenses		(379,309)	(351,022)
Finance costs	6	(195,981)	(222,981)
Share of profit of an associate		358	1,026
<b>PROFIT BEFORE TAX</b>	5	488,436	684,575
Income tax expense	7	(80,446)	(144,247)
<b>PROFIT FOR THE PERIOD</b>		407,990	540,328
Attributable to:			
Owners of the parent		386,585	539,416
Non-controlling interests		21,405	912
		407,990	540,328
<b>EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT</b>	9		
Basic (RMB)		11.32 cents	16.90 cents
Diluted (RMB)		11.29 cents	16.86 cents

# INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 June 2021

	<b>30 June 2021 (Unaudited) RMB'000</b>	30 June 2020 (Unaudited) RMB'000
<b>PROFIT FOR THE PERIOD</b>	<b>407,990</b>	540,328
<b>OTHER COMPREHENSIVE INCOME</b>		
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	<b>(7,663)</b>	(6,127)
Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:		
Equity investments designated at fair value through other comprehensive income: Changes in fair value	<b>34,372</b>	6,221
<b>OTHER COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX</b>	<b>26,709</b>	94
<b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD</b>	<b>434,699</b>	540,422
Attributable to:		
Owners of the parent	<b>413,294</b>	539,510
Non-controlling interests	<b>21,405</b>	912
	<b>434,699</b>	540,422

# INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

30 June 2021

	Notes	30 June 2021 (Unaudited) RMB'000	31 December 2020 (Audited) RMB'000
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment	10	3,837,869	3,677,698
Advance payments for property, plant and equipment and other intangible assets		367,568	323,678
Right-of-use assets		324,607	337,960
Goodwill		1,026,641	1,056,583
Other intangible assets	11	4,947,138	4,770,004
Investment in an associate		8,626	8,640
Long-term receivables		8,000	8,000
Equity investments designated at fair value through other comprehensive income		98,886	61,556
Financial assets at fair value through profit or loss	12	1,263	1,263
Pledged time deposits	14	200,000	300,000
Deferred tax assets		124,871	114,743
Total non-current assets		10,945,469	10,660,125
<b>CURRENT ASSETS</b>			
Inventories		626,736	612,303
Trade and notes receivables	13	1,768,725	1,553,089
Prepayments, other receivables and other assets		517,619	470,508
Due from related parties	22(b)	1,186	—
Financial assets at fair value through profit or loss	12	1,249,141	1,431,907
Restricted cash		36,834	37,473
Pledged time deposits	14	1,604,768	1,890,776
Time deposits with original maturity of over three months	14	150,000	109,000
Cash and cash equivalents	14	4,943,646	3,865,385
Total current assets		10,898,655	9,970,441
<b>CURRENT LIABILITIES</b>			
Trade and notes payables	15	722,619	485,262
Other payables and accruals		627,418	727,679
Derivative financial instruments		—	22,563
Interest-bearing bank and other borrowings	16	4,662,160	5,642,855
Government grants		81,363	45,193
Tax payable		238,549	308,346
Due to related parties	22(b)	4,422	2,196
Total current liabilities		6,336,531	7,234,094
<b>NET CURRENT ASSETS</b>		4,562,124	2,736,347
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		15,507,593	13,396,472

# INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

30 June 2021

	Notes	30 June 2021 (Unaudited) RMB'000	31 December 2020 (Audited) RMB'000
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<b>15,507,593</b>	13,396,472
<b>NON-CURRENT LIABILITIES</b>			
Interest-bearing bank and other borrowings	16	2,401,428	2,527,715
Convertible bonds	17	1,843,264	1,810,930
Long-term payables		51,681	52,199
Contingent consideration payables	18	322,481	638,556
Redemption liabilities on non-controlling interests	19	952,750	—
Employee defined benefit obligation		7,738	8,080
Government grants		166,407	185,657
Deferred tax liabilities		64,137	74,320
Total non-current liabilities		5,809,886	5,297,457
Net assets		9,697,707	8,099,015
<b>EQUITY</b>			
Equity attributable to owners of the parent			
Issued capital		455,835	417,991
Treasury shares		(279,558)	(279,558)
Share premium		1,815,686	1,042,005
Equity component of convertible bonds		292,398	292,398
Reserves		6,854,890	6,418,395
		9,139,251	7,891,231
Non-controlling interests		558,456	207,784
Total equity		9,697,707	8,099,015

# INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 June 2021

Attributable to owners of the parent

	Issued capital	Treasury shares	Share premium account	Equity component of convertible bonds	Safety production reserve*	Statutory surplus reserves*	Share award reserve*	Retained earnings*	Fair value reserve of financial assets at fair value through other comprehensive income*	Foreign currency translation reserve*	Total	Non-controlling interests	Total equity
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
At 1 January 2021	417,991	(279,558)	1,042,005	292,398	11,518	1,025,835	149,443	5,183,442	(3,771)	51,928	7,891,231	207,784	8,099,015
Profit for the period	–	–	–	–	–	–	–	386,585	–	–	386,585	21,405	407,990
Other comprehensive income for the period:													
Changes in fair value of investments, net of tax	–	–	–	–	–	–	–	–	34,372	–	34,372	–	34,372
Exchange differences on translation of foreign operations	–	–	–	–	–	–	–	–	–	(7,663)	(7,663)	–	(7,663)
Total comprehensive income for the period	–	–	–	–	–	–	–	386,585	34,372	(7,663)	413,294	21,405	434,699
Issue of shares (note a)	37,844	–	1,006,633	–	–	–	–	–	–	–	1,044,477	–	1,044,477
Appropriation to safety production reserve	–	–	–	–	10,637	–	–	(10,637)	–	–	–	–	–
Safety production reserve used	–	–	–	–	(2,846)	–	–	2,846	–	–	–	–	–
Share-based payment arrangements	–	–	–	–	–	–	23,201	–	–	–	23,201	2,294	25,495
Capital contribution from non-controlling interests (note b)	–	–	692,325	–	–	–	–	–	–	–	692,325	326,973	1,019,298
Redemption rights on non-controlling interests (note 19)	–	–	(925,277)	–	–	–	–	–	–	–	(925,277)	–	(925,277)
At 30 June 2021 (unaudited)	455,835	(279,558)	1,815,686	292,398	19,309	1,025,835	172,644	5,562,236	30,601	44,265	9,139,251	558,456	9,697,707

Notes:

- On 8 February 2021, 292,406,881 subscription shares have been allotted and issued to Hillhouse NEV Holdings Limited at the subscription price of HK\$4.28 per share.
- During the period, non-controlling shareholders contributed RMB1,019,298,000 in a subsidiary, Shandong Boan Biological Technology Co., Ltd. ("Boan Biotech").

# INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 June 2021

Attributable to owners of the parent

	Issued capital	Treasury shares	Share premium account	Equity component of convertible bonds	Safety production reserve*	Statutory surplus reserves*	Share award reserve*	Retained earnings*	Fair value reserve of financial assets at fair value through other comprehensive income*	Foreign currency translation reserve*	Total	Non-controlling interests	Total equity
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
At 1 January 2020 (restated)	420,565	(279,558)	2,671,071	292,398	—	907,644	99,871	4,730,023	(7,332)	(3,057)	8,831,625	(25,972)	8,805,653
Profit for the period	—	—	—	—	—	—	—	539,416	—	—	539,416	912	540,328
Other comprehensive income for the period:													
Changes in fair value of investments, net of tax	—	—	—	—	—	—	—	—	6,221	—	6,221	—	6,221
Exchange differences on translation of foreign operations	—	—	—	—	—	—	—	—	—	(6,127)	(6,127)	—	(6,127)
Total comprehensive income for the period	—	—	—	—	—	—	—	539,416	6,221	(6,127)	539,510	912	540,422
Repurchase of shares (note a)	—	(77,962)	—	—	—	—	—	—	—	—	(77,962)	—	(77,962)
Cancellation of treasury shares (note a)	(2,574)	77,962	(75,388)	—	—	—	—	—	—	—	—	—	—
Appropriation to safety production reserve	—	—	—	—	8,709	—	—	(8,709)	—	—	—	—	—
Safety production reserve used	—	—	—	—	(1,741)	—	—	1,741	—	—	—	—	—
Share-based payment arrangements	—	—	—	—	—	—	31,162	—	—	—	31,162	822	31,984
Final 2019 dividend (note 8)	—	—	—	—	—	—	—	(175,487)	—	—	(175,487)	—	(175,487)
Acquisition of a subsidiary under common control (note b)	—	—	(1,261,546)	—	—	—	—	—	—	—	(1,261,546)	—	(1,261,546)
Acquisition of non-controlling interests (note c)	—	—	(219,166)	—	—	—	—	—	—	—	(219,166)	178,743	(40,423)
At 30 June 2020 (unaudited)	417,991	(279,558)	1,114,971	292,398	6,968	907,644	131,033	5,086,984	(1,111)	(9,184)	7,668,136	154,505	7,822,641

## Notes:

- (a) During the period, the Company repurchased and cancelled 20,000,000 shares.
- (b) On 17 February 2020, the Group obtained control over Boan Biotech through a business combination involving entities under common control.
- (c) During the period, the Group acquired the non-controlling interests of Boan Biotech, and Boan Biotech became wholly owned by the Group.

\* These reserve accounts comprise the consolidated reserves of RMB6,854,890,000 in the consolidated statement of financial position as at 30 June 2021.

# INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2021

	Notes	30 June 2021 (Unaudited) RMB'000	30 June 2020 (Unaudited) RMB'000
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Profit before tax		488,436	684,575
Adjustments for:			
Share of profit of an associate		(358)	(1,026)
Depreciation and amortisation of non-current assets		270,260	254,687
Loss on disposal of non-current assets	5	165	31
Share-based payment expense	5	25,495	31,984
Bank interest income	4	(55,091)	(43,574)
Investment income from financial instruments at fair value through profit or loss	4	(25,244)	(26,387)
Changes in fair value of investments	4	(23,673)	(243)
Fair value adjustment of contingent considerations	18	45,608	23,582
Fair value adjustment of redemption liabilities on non-controlling interests	19	27,473	—
Interest income on loans to a related party		—	(1,283)
Interest expense	6	195,981	222,981
		<b>949,052</b>	<b>1,145,327</b>
Increase in inventories		(14,433)	(14,597)
Increase in trade and notes receivables		(215,615)	(145,953)
Increase in prepayments, other receivables and other assets		(50,203)	(47,671)
Increase in amounts due from related parties		(1,186)	(785)
Decrease/(increase) in pledged time deposits		28,622	(169,327)
Decrease/(increase) in restricted cash		639	(587)
Increase in trade and notes payables		237,357	148,504
Decrease in other payables and accruals		(82,981)	(112,794)
Increase in government grants		9,780	1,729
Increase in amounts due to related parties		2,226	858
Cash generated from operations		<b>863,258</b>	<b>804,704</b>
Interest paid		(145,572)	(171,283)
Income tax paid		(168,508)	(126,233)
Net cash flows from operating activities		<b>549,178</b>	<b>507,188</b>

# INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2021

	30 June 2021 (Unaudited) RMB'000	30 June 2020 (Unaudited) RMB'000
Net cash flows from operating activities	549,178	507,188
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchases of non-current assets	(730,797)	(671,214)
Purchases of investments	(431,000)	(2,559,220)
Proceeds from disposals of investments	625,000	3,414,618
Dividend income from investments	15,524	49,892
Proceeds from disposals of items of property, plant and equipment	4,441	307
Increase in government grants	7,140	13,700
(Increase)/decrease in time deposits with original maturity of over three months	(41,000)	411,460
Decrease/(increase) in pledged time deposits	991	(17,565)
Receipts of repayments from a related party	—	103,795
Interest received	56,410	39,173
Net cash flows (used in)/from investing activities	(493,291)	784,946
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
New loans	3,331,020	4,737,517
Repayment of loans	(4,428,995)	(4,376,526)
Decrease in pledged time deposits	356,395	671,646
Issue of shares	1,044,477	—
Payments for a business combination involving entities under common control	(361,683)	(723,367)
Capital contribution from non-controlling interests	1,019,298	—
Dividend paid to non-controlling interests	—	(5,000)
Repurchase of ordinary shares	—	(77,962)
Principal portion of lease payments	(8,832)	(8,949)
Net cash flows from financing activities	951,680	217,359
<b>NET INCREASE IN CASH AND CASH EQUIVALENTS</b>	<b>1,007,567</b>	<b>1,509,493</b>
Effect of foreign exchange rate changes, net	70,694	(58,987)
Cash and cash equivalents at 1 January	3,865,385	2,327,349
<b>CASH AND CASH EQUIVALENTS AT 30 JUNE</b>	<b>4,943,646</b>	<b>3,777,855</b>

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 1. CORPORATE INFORMATION

The interim condensed consolidated financial information for the six months ended 30 June 2021 was approved and authorised by the board of directors on 27 August 2021.

The Company was incorporated in Bermuda as an exempted company with limited liability under the Bermuda Companies Act on 2 July 2003. It was listed on the Singapore Exchange Securities Trading Limited (the “SGX”) on 5 May 2004, and has been delisted since 29 November 2012. On 9 July 2014, the Company succeeded its listing on the Main Board of the Stock Exchange of Hong Kong Limited (“SEHK”).

The Company is an investment holding company. The Company's subsidiaries are principally engaged in the development, production, marketing and sale of pharmaceutical products.

The registered office of the Company is located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. The principal place of business of the Company in Hong Kong is Suite 3207, Champion Tower, 3 Garden Road, Central, Hong Kong.

In the opinion of the directors, the ultimate holding company of the Company is Luye Life Sciences Group Ltd., which is incorporated in Bermuda.

## 2. BASIS OF PREPARATION AND CHANGES TO THE GROUP'S ACCOUNTING POLICIES

### 2.1 Basis of preparation

The interim condensed consolidated financial information for the six months ended 30 June 2021 has been prepared in accordance with International Accounting Standard 34 *Interim Financial Reporting*.

The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements as at 31 December 2020.

The interim condensed consolidated financial information has been prepared under the historical cost convention, except for equity investments designated at fair value through other comprehensive income, financial assets at fair value through profit or loss, notes receivable, redemption liabilities on non-controlling interests and contingent consideration payables which have been measured at fair value. The interim condensed consolidated financial information is presented in Renminbi (“RMB”) and all values are rounded to the nearest thousand except when otherwise indicated.

## 2. BASIS OF PREPARATION AND CHANGES TO THE GROUP'S ACCOUNTING POLICIES (Continued)

### 2.2 Changes in accounting policies and disclosures

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2020, except for the adoption of the following revised International Financial Reporting Standards ("IFRSs") for the first time for the current period's financial information.

Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16      *Interest Rate Benchmark Reform — Phase 2*

The nature and impact of the revised IFRSs are described below:

Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 address issues not dealt with in the previous amendments which affect financial reporting when an existing interest rate benchmark is replaced with an alternative risk-free rate ("RFR"). The phase 2 amendments provide a practical expedient to allow the effective interest rate to be updated without adjusting the carrying amount of financial assets and liabilities when accounting for changes in the basis for determining the contractual cash flows of financial assets and liabilities, if the change is a direct consequence of the interest rate benchmark reform and the new basis for determining the contractual cash flows is economically equivalent to the previous basis immediately preceding the change. In addition, the amendments permit changes required by the interest rate benchmark reform to be made to hedge designations and hedge documentation without the hedging relationship being discontinued. Any gains or losses that could arise on transition are dealt with through the normal requirements of IFRS 9 to measure and recognise hedge ineffectiveness. The amendments also provide a temporary relief to entities from having to meet the separately identifiable requirement when an RFR is designated as a risk component. The relief allows an entity, upon designation of the hedge, to assume that the separately identifiable requirement is met, provided the entity reasonably expects the RFR risk component to become separately identifiable within the next 24 months. Furthermore, the amendments require an entity to disclose additional information to enable users of financial statements to understand the effect of interest rate benchmark reform on an entity's financial instruments and risk management strategy.

The Group had certain interest-bearing bank and other borrowings denominated in foreign currencies based on various Interbank Offered Rates as at 30 June 2021. Since the interest rates of these borrowings were not replaced by RFRs during the period, the amendment did not have any impact on the financial position and performance of the Group. If the interest rates of these borrowings are replaced by RFRs in a future period, the Group will apply this practical expedient upon the modification of these borrowings provided that the "economically equivalent" criterion is met.

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 3. OPERATING SEGMENT INFORMATION

The Group manages its businesses by type of products. The Group's chief operating decision maker is the Chief Executive Officer, who reviews revenue from and results of the major type of products sold for the purpose of resources allocation and assessment of segment performance. Segment result is evaluated based on gross profit less selling expenses allocated. No analysis of the Group's assets and liabilities by operating segment is disclosed as it is not regularly provided to the chief operating decision maker for review.

For the six months ended 30 June 2021 (Unaudited)

	Oncology drugs RMB'000	Cardio- vascular system drugs RMB'000	Alimentary tract and metabolism drugs RMB'000	Central nervous system drugs RMB'000	Others RMB'000	Total RMB'000
<b>Segment revenue</b>						
Sales of products and know-how*	926,998	800,653	458,331	692,795	71,327	2,950,104
Out-licensing agreements	—	—	—	1,560	—	1,560
Total revenue	926,998	800,653	458,331	694,355	71,327	2,951,664
Segment results	590,934	325,883	68,874	179,691	17,571	1,182,953
Other income and gains						162,288
Administrative expenses						(281,873)
Other expenses						(379,309)
Finance costs						(195,981)
Share of profit of an associate						358
Profit before tax						488,436

\* The amount included sales of product know-how of RMB480,000,000.

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 3. OPERATING SEGMENT INFORMATION (Continued)

For the six months ended 30 June 2020 (Unaudited)

	Oncology drugs RMB'000	Cardio- vascular system drugs RMB'000	Alimentary tract and metabolism drugs RMB'000	Central nervous system drugs RMB'000	Others RMB'000	Total RMB'000
<b>Segment revenue</b>						
Sales of products	1,334,214	429,507	391,313	746,335	60,832	2,962,201
Total revenue	1,334,214	429,507	391,313	746,335	60,832	2,962,201
Segment results	771,863	153,170	104,106	272,149	22,714	1,324,002
Other income and gains						181,568
Administrative expenses						(248,018)
Other expenses						(351,022)
Finance costs						(222,981)
Share of profit of an associate						1,026
Profit before tax						684,575

## 4. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

	For the six months ended 30 June	
	2021 (Unaudited) RMB'000	2020 (Unaudited) RMB'000
Revenue from contracts with customers	2,951,664	2,962,201

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 4. REVENUE, OTHER INCOME AND GAINS (Continued)

### Disaggregated revenue information for revenue from contracts with customers

For the six months ended 30 June 2021 (Unaudited)

	Oncology drugs RMB'000	Cardio- vascular system drugs RMB'000	Alimentary tract and metabolism drugs RMB'000	Central nervous system drugs RMB'000	Others RMB'000	Total RMB'000
<b>Type of goods or services</b>						
Sales of products and know-how*	926,998	800,653	458,331	692,795	71,327	2,950,104
Out-licensing agreements	—	—	—	1,560	—	1,560
Total revenue from contracts with customers	926,998	800,653	458,331	694,355	71,327	2,951,664
<b>Geographical markets</b>						
Mainland China	926,998	794,836	455,982	241,073	70,816	2,489,705
Other countries	—	5,817	2,349	453,282	511	461,959
Total revenue from contracts with customers	926,998	800,653	458,331	694,355	71,327	2,951,664
<b>Timing of revenue recognition</b>						
Transferred at a point in time	926,998	800,653	458,331	694,355	71,327	2,951,664
Total revenue from contracts with customers	926,998	800,653	458,331	694,355	71,327	2,951,664

\* The amount included sales of product know-how of RMB480,000,000.

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 4. REVENUE, OTHER INCOME AND GAINS (Continued)

### Disaggregated revenue information for revenue from contracts with customers (Continued)

For the six months ended 30 June 2020 (Unaudited)

	Oncology drugs RMB'000	Cardio- vascular system drugs RMB'000	Alimentary tract and metabolism drugs RMB'000	Central nervous system drugs RMB'000	Others RMB'000	Total RMB'000
<b>Type of goods or services</b>						
Sale of products	1,334,214	429,507	391,313	746,335	60,832	2,962,201
Total revenue from contracts with customers	1,334,214	429,507	391,313	746,335	60,832	2,962,201
<b>Geographical markets</b>						
Mainland China	1,334,214	425,466	390,122	141,251	60,402	2,351,455
Other countries	—	4,041	1,191	605,084	430	610,746
Total revenue from contracts with customers	1,334,214	429,507	391,313	746,335	60,832	2,962,201
<b>Timing of revenue recognition</b>						
Transferred at a point in time	1,334,214	429,507	391,313	746,335	60,832	2,962,201
Total revenue from contracts with customers	1,334,214	429,507	391,313	746,335	60,832	2,962,201

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 4. REVENUE, OTHER INCOME AND GAINS (Continued)

	For the six months ended 30 June	
	2021	2020
	(Unaudited) RMB'000	(Unaudited) RMB'000
<b>Other income and gains</b>		
Bank interest income	55,091	43,574
Government grants	54,177	92,668
Changes in fair value of investments	23,673	243
Investment income from financial instruments at fair value through profit or loss	25,244	26,387
Interest income on loans to a related party	—	1,283
Foreign exchange gain, net	—	15,076
Others	4,103	2,337
	<b>162,288</b>	<b>181,568</b>

## 5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging:

	For the six months ended 30 June	
	2021	2020
	(Unaudited) RMB'000	(Unaudited) RMB'000
Depreciation of items of property, plant and equipment	150,336	135,324
Amortisation of other intangible assets	106,483	105,837
Depreciation of right-of-use assets	13,441	13,526
Auditor's remuneration	2,900	2,200
Research and development costs	303,742	326,142
Cost of products sold	997,983	764,336
Foreign exchange loss, net	1,164	—
Share-based payment expense	25,495	31,984
Remeasurement of contingent considerations	45,608	23,582
Fair value adjustment of redemption liabilities on non-controlling interests	27,473	—
Loss on disposal of non-current assets	165	31

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 6. FINANCE COSTS

	For the six months ended 30 June	
	2021 (Unaudited) RMB'000	2020 (Unaudited) RMB'000
Interest on bank loans	119,280	137,647
Interest on convertible bonds	64,971	66,809
Interest on discounted notes receivable	6,604	4,573
Interest on discounted letters of credit	4,748	11,646
Interest on lease liabilities	378	799
Amortised interest on discounted long-term payables	—	1,507
	<b>195,981</b>	<b>222,981</b>

## 7. INCOME TAX EXPENSE

The Group is subject to income tax on an entity basis on profit arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the interim condensed consolidated statement of profit or loss are:

	For the six months ended 30 June	
	2021 (Unaudited) RMB'000	2020 (Unaudited) RMB'000
Current tax	100,508	148,294
Deferred tax	(20,062)	(4,047)
Total tax charge for the period	<b>80,446</b>	<b>144,247</b>

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 8. DIVIDENDS

	For the six months ended 30 June	
	2021 (Unaudited) RMB'000	2020 (Unaudited) RMB'000
Final declared and paid — nil (2019: RMB0.054) per ordinary share	—	175,487

Note: No interim dividend was declared by the Company for the six months ended 30 June 2021 (six months ended 30 June 2020: Nil).

## 9. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 3,414,484,434 (six months ended 30 June 2020: 3,191,219,590) in issue during the period. The number of shares for the current period has been arrived at after eliminating the shares of the Company held under the share award scheme and shares repurchased.

The calculation of the diluted earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent, adjusted to reflect the interest on the convertible bonds, where applicable. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares in issue during the period, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed conversion of all dilutive potential ordinary shares into ordinary shares.

The calculations of basic and diluted earnings per share are based on:

	For the six months ended 30 June	
	2021 (Unaudited) RMB'000	2020 (Unaudited) RMB'000
<b>Earnings</b>		
Profit attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation	386,585	539,416
Interest on convertible bonds	64,971	66,809
Profit attributable to ordinary equity holders of the parent before interest on convertible bonds	451,556*	606,225

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 9. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (Continued)

	For the six months ended 30 June	
	2021 (Unaudited)	2020 (Unaudited)
<b>Shares</b>		
Weighted average number of ordinary shares in issue during the period in the basic earnings per share calculation	3,414,484,434	3,191,219,590
Effect of dilution — weighted average number of ordinary shares:		
Equity-settled share award scheme	10,971,775	7,324,059
Convertible bonds	296,760,759	291,231,055
	<b>3,722,216,968*</b>	3,489,774,704

\* Because the diluted earnings per share amount is increased when taking the convertible bonds into account, the convertible bonds had an anti-dilutive effect on the basic earnings per share for the period and were ignored in the calculation of diluted earnings per share. Therefore, the diluted earnings per share amounts are based on the profit for the period of RMB386,585,000, and the weighted average number of ordinary shares of 3,425,456,209 in issue during the period.

## 10. PROPERTY, PLANT AND EQUIPMENT

	30 June 2021 (Unaudited) RMB'000	31 December 2020 (Audited) RMB'000
Carrying amount at beginning of period	3,677,698	3,276,293
Additions	323,889	666,604
Depreciation provided during the period	(150,336)	(268,223)
Exchange realignment	(8,776)	5,247
Disposals	(4,606)	(2,223)
Carrying amount at end of period	<b>3,837,869</b>	3,677,698

As at 30 June 2021, the Group was applying for the certificates of ownership for certain properties with a net book value of RMB108,755,000 (31 December 2020: RMB110,123,000). The directors of the Company are of the opinion that the use of the properties and the conduct of operating activities at those properties referred to above are not affected by the fact the Group had not yet obtained the relevant property title certificates. The Group is not able to assign, transfer or mortgage these assets until these certificates are obtained.

As at 30 June 2021, certain of the Group's property, plant and equipment with a net carrying amount of approximately RMB458,165,000 (31 December 2020: RMB186,649,000) were pledged to secure bank loans (note 16).

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 11. OTHER INTANGIBLE ASSETS

	<b>30 June 2021 (Unaudited) RMB'000</b>	31 December 2020 (Audited) RMB'000
Carrying amount at beginning of period	4,770,004	4,685,303
Additions	345,517	503,367
Amortisation provided during the period	(106,483)	(215,196)
Exchange realignment	(61,900)	(203,470)
Carrying amount at end of period	<b>4,947,138</b>	4,770,004

## 12. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

	<b>30 June 2021 (Unaudited) RMB'000</b>	31 December 2020 (Audited) RMB'000
<b>Current</b>		
Other unlisted investments, at fair value	1,232,991	1,412,659
Listed equity investment, at fair value	16,150	19,248
	<b>1,249,141</b>	1,431,907
<b>Non-current</b>		
Unlisted equity investments, at fair value	1,263	1,263
	<b>1,250,404</b>	1,433,170

The above other unlisted investments represent investments in certain wealth management products issued by commercial banks with expected interest rates ranging from 3.50% to 5.30% per annum with a maturity period within one year in the People's Republic of China (the "PRC"). The fair values of the financial products approximate to their costs plus expected interest. The fair value of the listed equity investment is derived from quoted price in an active market.

The fair value of the unlisted equity investments which are not quoted in an active market is valued using observable inputs such as recently executed transaction prices in securities of the issuer or comparable issuers and yield curves.

As at 30 June 2021, other unlisted investments of RMB181,428,000 (31 December 2020: RMB10,000,000) were pledged to secure intra-group notes payable.

As at 30 June 2021, other unlisted investments of RMB24,572,000 (31 December 2020: RMB90,000,000) were pledged to secure notes payable (note 15).

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 12. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS (Continued)

As at 30 June 2021, other unlisted investments of nil (31 December 2020: RMB200,000,000) were pledged to secure bank loans (note 16).

As at 30 June 2021, other unlisted investments of nil (31 December 2020: RMB100,000,000) were pledged to secure letters of credit.

## 13. TRADE AND NOTES RECEIVABLES

	<b>30 June 2021 (Unaudited) RMB'000</b>	31 December 2020 (Audited) RMB'000
Trade receivables	1,453,388	954,645
Notes receivable	318,953	602,614
	<b>1,772,341</b>	1,557,259
Less: Impairment of trade receivables	(3,616)	(4,170)
	<b>1,768,725</b>	1,553,089

The Group's trading terms with its customers are mainly on credit. The credit period is generally one month to three months, extending up to six months for major customers. The Group seeks to maintain strict control over its outstanding receivables and overdue balances are reviewed regularly by senior management. In view of the aforementioned and the fact that the Group's trade receivables relate to large number of diversified customers, there is no significant concentration of credit risk. Trade receivables are non-interest-bearing.

The notes receivable are due within twelve months. As at 30 June 2021, notes receivable of RMB318,953,000 (31 December 2020: RMB602,614,000) whose fair values approximate to their carrying values were classified as financial assets at fair value through other comprehensive income under IFRS 9. The fair value changes of these notes receivable at fair value through other comprehensive income were insignificant in the six months ended 30 June 2021.

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date, is as follows:

	<b>30 June 2021 (Unaudited) RMB'000</b>	31 December 2020 (Audited) RMB'000
Less than 3 months	1,394,106	887,792
Between 3 and 6 months	44,414	47,101
Between 6 and 12 months	13,023	17,067
Between 1 and 2 years	653	1,267
Over 2 years	1,192	1,418
	<b>1,453,388</b>	954,645

## 13. TRADE AND NOTES RECEIVABLES (Continued)

As at 30 June 2021, the Group has pledged notes receivable of RMB6,302,000 (31 December 2020: Nil) and intra-group notes receivable of RMB20,000,000 (31 December 2020: RMB15,000,000) to secure notes payable (note 15).

As at 30 June 2021, the Group has pledged notes receivable of RMB5,860,000 (31 December 2020: RMB177,135,000) and intra-group notes receivable of RMB175,000,000 (31 December 2020: RMB10,000,000) to secure bank loans (note 16).

As at 30 June 2021, notes receivable and intra-group notes receivable of RMB19,955,000 (31 December 2020: RMB929,000) and RMB470,000,000 (31 December 2020: RMB540,975,000) were discounted.

As at 30 June 2021, the Group endorsed certain notes receivable accepted by the certain banks in the PRC (the “Endorsed Notes”) to certain of its suppliers in order to settle the trade and other payables due to such suppliers with a carrying amount in aggregate of RMB350,962,000 (31 December 2020: RMB256,227,000) (the “Endorsement”). The Endorsed Notes have a maturity from one to twelve months as at 30 June 2021. In accordance with the Law of Negotiable Instruments in the PRC, the holders of the Endorsed Notes have a right of recourse against the Group if the PRC banks default (the “Continuing Involvement”).

In the opinion of the directors, the Group has transferred substantially all the risks and rewards relating to certain Endorsed Notes accepted by large and reputable banks with amount of RMB277,514,000 (31 December 2020: RMB167,955,000) (the “Derecognised Notes”). Accordingly, it has derecognised the full carrying amounts of the Derecognised Notes and the associated trade and other payables settled by the Endorsed Notes. The maximum exposure to loss from the Group’s Continuing Involvement in the Derecognised Notes and the undiscounted cash flows to repurchase these Derecognised Notes is equal to their carrying amounts. In the opinion of the directors, the fair values of the Group’s Continuing Involvement in the Derecognised Notes are not significant.

The Group continued to recognise the full carrying amount of the remaining Endorsed Notes and the associated trade and other payables settled with an amount of RMB73,448,000 as at 30 June 2021 (31 December 2020: RMB88,272,000) because the directors of the Company believe that the Group has retained the substantial risks and rewards, which include default risks relating to such remaining Endorsed Notes.

During the period, the Group has not recognised any gain or loss on the date of transfer of the Derecognised Notes. No gains or losses were recognised from the continuing involvement, both during the period or cumulatively. The Endorsement has been made evenly throughout the period.

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 14. CASH AND CASH EQUIVALENTS AND PLEDGED TIME DEPOSITS

	<b>30 June 2021 (Unaudited) RMB'000</b>	31 December 2020 (Audited) RMB'000
Cash and bank balances	4,665,873	3,484,938
Time deposits	2,232,541	2,680,223
	<b>6,898,414</b>	6,165,161
Less:		
Pledged time deposits for letters of credit	(15,790)	(16,781)
Pledged time deposits for bank loans	(743,601)	(1,099,995)
Current pledged time deposits for notes payable	(174,291)	(53,940)
Current pledged time deposits for intra-group notes payable	(671,086)	(720,060)
Non-current pledged time deposits for notes payable	(5,730)	(150)
Non-current pledged time deposits for intra-group notes payable	(194,270)	(299,850)
Non-pledged time deposits with original maturity over three months when acquired	(150,000)	(109,000)
Cash and cash equivalents	<b>4,943,646</b>	3,865,385
Denominated in RMB	4,455,427	3,786,523
Denominated in US\$	428,155	36,492
Denominated in EUR	15,572	29,997
Denominated in others	44,492	12,373
Cash and cash equivalents	<b>4,943,646</b>	3,865,385

The RMB is not freely convertible into other currencies. However, under Mainland China's Foreign Exchange Control Regulations and Administration of Settlement, Sales and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business. The remittance of funds out of Mainland China is subject to exchange restrictions imposed by the PRC government.

Cash at banks earns interest at floating rates based on daily bank deposit rates. Time deposits are made for varying periods of between one day and twelve months depending on the immediate cash requirements of the Group, and earn interest at the respective short term time deposit rates. The bank balances and pledged time deposits are deposited with creditworthy banks with no recent history of default.

As at 30 June 2021, time deposits of RMB743,601,000 (31 December 2020: RMB1,099,995,000) were pledged to secure bank loans (note 16).

As at 30 June 2021, time deposits of RMB865,356,000 (31 December 2020: RMB1,019,910,000) were pledged to secure intra-group notes payable.

As at 30 June 2021, time deposits of RMB180,021,000 (31 December 2020: RMB54,090,000) were pledged to secure Group's notes payable (note 15).

As at 30 June 2021, time deposits of RMB15,790,000 (31 December 2020: RMB16,781,000) were pledged to secure letters of credit.

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 15. TRADE AND NOTES PAYABLES

	<b>30 June 2021 (Unaudited) RMB'000</b>	31 December 2020 (Audited) RMB'000
Trade payables	485,106	326,172
Notes payable	237,513	159,090
	<b>722,619</b>	485,262

An ageing analysis of the trade and notes payables as at the end of the reporting period, based on the invoice date, is as follows:

	<b>30 June 2021 (Unaudited) RMB'000</b>	31 December 2020 (Audited) RMB'000
Less than 3 months	572,951	456,647
Between 3 and 6 months	88,839	17,952
Between 6 and 12 months	55,675	6,516
Between 1 and 2 years	2,511	2,042
Over 2 years	2,643	2,105
	<b>722,619</b>	485,262

The trade payables are non-interest-bearing and are normally settled on 90-day terms.

As at 30 June 2021, the Group's notes payable were secured by certain of the Group's notes receivable, intra-group notes receivable, other unlisted investments and time deposits amounting to approximately RMB6,302,000 (31 December 2020: Nil) (note 13), RMB20,000,000 (31 December 2020: RMB15,000,000) (note 13), RMB24,572,000 (31 December 2020: RMB90,000,000) (note 12) and RMB180,021,000 (31 December 2020: RMB54,090,000) (note 14), respectively.

The maturity dates of the notes payable are within twelve months.

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 16. INTEREST-BEARING BANK AND OTHER BORROWINGS

As at 30 June 2021

	Effective interest rate (%)	Maturity	RMB'000
<b>Current</b>			
Bank loans — secured			
RMB70,093,126 bank loan	1-year LPR+0.94	20 December 2021	70,093
RMB45,000,000 bank loan	1-year LPR-0.14	12 March 2022	45,000
RMB200,200,000 bank loan	1-year LPR+0.15	19 March 2022	200,200
RMB200,000,000 bank loan	1-year LPR+0.20	11 March 2022	200,000
RMB100,000,000 bank loan	1-year LPR+0.20	3 March 2022	100,000
RMB95,116,111 bank loan	1-year LPR+0.15	27 August 2021	95,116
RMB150,163,125 bank loan	4.35	18 April 2022	150,163
RMB125,000,000 bank loan	3.70	21 July 2021	125,000
RMB125,000,000 bank loan	3.70	3 August 2021	125,000
RMB175,000,000 bank loan	4.10	21 August 2021	175,000
RMB50,000,000 bank loan	4.50	4 November 2021	50,000
RMB91,599,316 bank loan	4.25	19 July 2021	91,599
RMB43,084,202 bank loan	4.00	13 September 2021	43,084
RMB80,444,930 bank loan	4.00	17 September 2021	80,445
RMB27,227,200 bank loan	4.00	15 October 2021	27,227
RMB56,270,875 bank loan	4.00	17 December 2021	56,271
RMB81,511,111 bank loan	4.00	9 July 2021	81,511
RMB20,331,111 bank loan	4.00	28 July 2021	20,331
RMB73,000,000 bank loan	4.50	7 January 2022	73,000
RMB57,000,000 bank loan	4.10	21 December 2021	57,000
RMB150,000,000 bank loan	4.10	1 April 2022	150,000
RMB49,000,000 bank loan	4.80	28 March 2022	49,000
RMB99,041,807 bank loan	4.13	18 June 2022	99,042
RMB300,000,000 bank loan	4.13	29 July 2021	300,000
RMB80,000,000 bank loan	4.35	7 December 2021	80,000
RMB50,000,000 bank loan	4.00	20 August 2021	50,000
RMB50,000,000 bank loan	4.30	4 January 2022	50,000
RMB5,460,000 bank loan	1-year LPR+0.30	28 December 2021	5,460
US\$15,000,000 bank loan	1.70	21 July 2021	98,450
EUR18,000,000 bank loan	1.30	10 February 2022	139,116
EUR12,000,000 bank loan	1.80	15 October 2021	92,234
EUR12,600,000 bank loan	3-month EURIBOR+1.00	11 August 2021	96,978
EUR10,000,000 bank loan	1.35	20 May 2022	76,894
EUR8,757,399 bank loan	1.35	13 May 2022	67,339
EUR30,000,000 bank loan	3-month EURIBOR+0.60	20 April 2022	230,864
EUR1,200,000 bank loan	1.50	20 August 2021	9,232
EUR13,400,000 bank loan	1.30	12 March 2022	103,404

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

As at 30 June 2021 (Continued)

	Effective interest rate (%)	Maturity	RMB'000
Current portion of long-term bank loans — secured			
RMB10,088,813 bank loan	4.90	21 December 2021	10,089
RMB10,088,813 bank loan	4.90	21 June 2022	10,089
RMB1,026,976 bank loan	4.60	12 November 2021	1,027
RMB17,561,296 bank loan	4.60	12 May 2022	17,561
RMB5,000,000 bank loan	5-year LPR+0.05	15 April 2022	5,000
US\$2,700,000 bank loan	3-month LIBOR+2.85	30 June 2022	17,442
US\$20,700,000 bank loan	3-month LIBOR+2.85	30 June 2022	133,724
US\$21,560,400 bank loan	3-month LIBOR+2.85	30 June 2022	139,282
US\$3,413,730 bank loan	3-month LIBOR+2.85	30 June 2022	22,053
EUR81,492 bank loan	3-month EURIBOR+1.70	14 August 2021	626
Discounted notes receivable	3.80	1 September 2021	29,877
	2.85	27 August 2021	99,533
	3.90	13 August 2021	139,333
	4.20	17 September 2021	49,504
	4.20	20 September 2021	49,534
	2.80	20 August 2021	640
	2.80	18 September 2021	1,000
	2.80	1 October 2021	687
	2.80	27 November 2021	500
	2.80	11 December 2021	784
	2.75	23 December 2021	12,590
	2.80	28 December 2021	3,754
	3.90	13 August 2021	10,000
	2.95	8 September 2021	49,990
	3.19	9 November 2021	39,529
Discounted letters of credit	4.15	27 January 2022	48,923
	3.90	21 January 2022	195,945
Lease liabilities	3.99	30 June 2022	9,091
			4,662,160

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

As at 30 June 2021 (Continued)

	Effective interest rate (%)	Maturity	RMB'000
<b>Non-current</b>			
Bank loans — secured			
RMB125,000,000 bank loan	4.90	21 December 2022– 6 June 2025	125,000
RMB245,000,000 bank loan	5-year LPR+0.05	15 October 2022– 30 September 2026	245,000
RMB343,583,210 bank loan	4.60	11 November 2022– 30 September 2026	343,583
US\$11,709,515 bank loan	3-month LIBOR+2.85	30 June 2023– 30 June 2025	75,645
US\$89,721,442 bank loan	3-month LIBOR+2.85	30 June 2023– 30 June 2025	579,609
US\$93,561,959 bank loan	3-month LIBOR+2.85	30 June 2023– 30 June 2025	604,420
US\$17,191,011 bank loan	3-month LIBOR+2.85	30 June 2023– 30 June 2025	111,056
EUR40,393,298 bank loan	3-month EURIBOR+1.70	14 August 2022– 14 August 2023	310,471
Lease liabilities	3.99	1 July 2022– 30 August 2023	6,644
			2,401,428
Total interest-bearing loans and borrowings			7,063,588
Convertible bonds	7.29	2021–2024	1,843,264
			8,906,852

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

As at 31 December 2020

	Effective interest rate (%)	Maturity	RMB'000
<b>Current</b>			
Bank loans — secured			
RMB50,063,135 bank loan	1-year LPR+0.08	2 March 2021	50,064
RMB70,093,126 bank loan	1-year LPR+0.94	20 December 2021	70,093
RMB200,229,583 bank loan	1-year LPR+0.08	19 March 2021	200,230
RMB100,123,750 bank loan	1-year LPR	24 March 2021	100,124
RMB200,247,500 bank loan	1-year LPR	14 March 2021	200,248
RMB95,116,111 bank loan	1-year LPR+0.15	27 August 2021	95,116
RMB110,139,563 bank loan	4.57	11 November 2021	110,140
RMB52,105,139 bank loan	3.95	15 January 2021	52,105
RMB22,253,905 bank loan	3.95	15 January 2021	22,254
RMB17,154,367 bank loan	3.95	15 January 2021	17,154
RMB43,773,323 bank loan	3.95	16 March 2021	43,773
RMB80,692,698 bank loan	3.95	19 March 2021	80,693
RMB27,622,140 bank loan	3.95	16 April 2021	27,622
RMB56,312,176 bank loan	4.25	17 June 2021	56,312
RMB101,822,222 bank loan	4.00	20 January 2021	101,822
RMB71,166,667 bank loan	4.00	29 January 2021	71,167
RMB20,333,333 bank loan	4.00	29 January 2021	20,333
RMB30,500,000 bank loan	4.00	29 January 2021	30,500
RMB81,511,111 bank loan	4.00	8 January 2021	81,511
RMB71,298,889 bank loan	4.00	13 January 2021	71,299
RMB194,218,250 bank loan	4.05	27 March 2021	194,218
RMB150,181,250 bank loan	4.35	26 March 2021	150,181
RMB57,145,667 bank loan	4.60	11 June 2021	57,146
RMB125,128,472 bank loan	3.70	21 July 2021	125,128
RMB125,128,472 bank loan	3.70	3 August 2021	125,128
RMB175,199,306 bank loan	4.10	21 August 2021	175,199
RMB50,062,500 bank loan	4.50	4 November 2021	50,063
RMB81,448,889 bank loan	4.00	20 January 2021	81,449
RMB300,237,760 bank loan	4.13	29 July 2021	300,238
RMB80,112,954 bank loan	4.35	7 December 2021	80,113
HK\$194,423,387 bank loan	1.08	15 March 2021	163,635
US\$7,006,085 bank loan	2.85	16 April 2021	45,714
US\$8,005,707 bank loan	2.35	22 April 2021	52,236
US\$30,022,255 bank loan	1-month LIBOR+1.10	6 January 2021	195,892
US\$40,379,432 bank loan	1.70	23 June 2021	263,472
US\$15,134,234 bank loan	1.70	21 July 2021	98,749
US\$22,404,985 bank loan	1-month LIBOR+0.80	29 January 2021	146,190
EUR10,081,130 bank loan	1.20	25 May 2021	80,901
EUR10,004,815 bank loan	1.45	16 April 2021	80,289
EUR11,005,306 bank loan	1.45	22 April 2021	88,318
EUR25,051,198 bank loan	1.42	8 April 2021	201,036
EUR12,617,110 bank loan	3-month EURIBOR+1.00	11 August 2021	101,252
EUR20,000,000 bank loan	1.02	23 April 2021	165,763

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

As at 31 December 2020 (Continued)

	Effective interest rate (%)	Maturity	RMB'000
Current portion of long-term bank loans — secured			
RMB3,204,167 bank loan	4.90	21 June 2021	3,204
RMB10,000,000 bank loan	4.90	21 December 2021	10,000
RMB340,278 bank loan	4.90	21 March 2021	340
RMB10,124,542 bank loan	4.13	18 June 2021	10,125
US\$1,224,488 bank loan	3-month LIBOR+2.85	30 June 2021	7,990
US\$12,457,158 bank loan	3-month LIBOR+2.85	30 June 2021	81,282
US\$13,103,880 bank loan	3-month LIBOR+2.85	30 June 2021	85,502
US\$2,408,816 bank loan	3-month LIBOR+2.85	30 June 2021	15,717
EUR81,492 bank loan	3-month EURIBOR+1.70	15 March 2021	654
Discounted notes receivable			
	2.85	27 August 2021	98,108
	3.40	27 February 2021	39,772
	3.55	28 April 2021	29,652
	3.15	28 March 2021	922
	2.80	27 February 2021	29,859
	2.89	4 May 2021	49,500
	2.79	25 May 2021	964
	4.20	17 September 2021	48,454
	4.20	20 September 2021	48,484
	3.19	9 November 2021	38,892
	3.90	13 August 2021	146,588
Discounted letters of credit			
	2.57	7 April 2021	19,863
	3.85	4 February 2021	199,284
	3.73	18 January 2021	99,816
	3.38	10 June 2021	40,000
Lease liabilities	3.93	31 December 2021	13,013
			5,642,855

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

As at 31 December 2020 (Continued)

	Effective interest rate (%)	Maturity	RMB'000
<b>Non-current</b>			
Bank loans — secured			
RMB135,000,000 bank loan	4.90	21 June 2022– 6 June 2025	135,000
RMB250,000,000 bank loan	4.90	15 April 2022– 30 September 2026	250,000
RMB90,000,000 bank loan	4.13	18 June 2022	90,000
US\$14,580,000 bank loan	3-month LIBOR+2.85	1 January 2022– 30 June 2025	95,133
US\$111,780,000 bank loan	3-month LIBOR+2.85	1 January 2022– 30 June 2025	729,353
US\$116,426,160 bank loan	3-month LIBOR+2.85	1 January 2022– 30 June 2025	759,669
US\$20,482,380 bank loan	3-month LIBOR+2.85	1 January 2022– 30 June 2025	133,646
EUR40,272,226 bank loan	3-month EURIBOR+1.70	1 January 2022– 30 August 2023	323,185
Lease liabilities	3.93	1 January 2022– 30 August 2023	11,729
			2,527,715
Total interest-bearing loans and borrowings			8,170,570
Convertible bonds	7.29	2021–2024	1,810,930
			9,981,500

Certain of the Group's bank loans are secured by:

- (i) the pledge of certain of the Group's time deposits of RMB743,601,000 (31 December 2020: RMB1,099,995,000) (note 14);
- (ii) the pledge of certain of the Group's notes receivable of RMB5,860,000 (31 December 2020: RMB177,135,000) (note 13);
- (iii) the pledge of certain of the Group's intra-group notes receivable of RMB175,000,000 (31 December 2020: RMB10,000,000) (note 13);
- (iv) the pledge of certain of the Group's property, plant and equipment, which had an aggregate carrying value at the end of the reporting period of approximately RMB458,165,000 (31 December 2020: RMB186,649,000) (note 10);
- (v) the pledge of certain of the Group's other unlisted investments with a carrying amount of nil (31 December 2020: RMB200,000,000) (note 12); and
- (vi) the pledge of certain of the Group's subsidiaries' shares.

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 17. CONVERTIBLE BONDS

On 9 July 2019, the Company issued 1.50 per cent convertible bonds with an aggregate principal amount of US\$300,000,000. There was no movement in the number of these convertible bonds during the period. The bonds are convertible at the option of the bondholders into ordinary shares with the initial conversion price of HK\$8.15 per share at any time on or after 19 August 2019 and up to the close of business on the date falling ten days prior to 9 July 2024. The bonds are redeemable at the option of the bondholders at a 3.75 per cent gross yield upon early redemption. Any convertible bonds not converted will be redeemed on 9 July 2024 at 112.25 per cent of its principal amount together with accrued but unpaid interest thereon. The bonds carry interest at a rate of 1.50 per cent per annum, which is payable semi-annually in arrears on 9 January and 9 July. As at 30 June 2021, the conversion price was HK\$7.90 per share after adjustment as a result of the declaration of the dividends. None of the convertible bonds were repaid or redeemed during the period.

## 18. CONTINGENT CONSIDERATION PAYABLES

As part of the sale and purchase agreement in relation to the acquisition of Boan Biotech, portions of the consideration were determined to be contingent, based on the grant by the competent authority in China of the marketing authorisation for LY01008 and LY06006, respectively. LY01008 and LY06006 are two biosimilar products under research and development by Boan Biotech. The movement of the fair value of contingent consideration payables is as follows:

	<b>30 June 2021 (Unaudited) RMB'000</b>	31 December 2020 (Audited) RMB'000
At the beginning of period	638,556	—
Arising from acquisition of Boan Biotech	—	614,795
Payment	(361,683)	—
Fair value changes	45,608	23,761
At the end of period	<b>322,481</b>	638,556

The fair values of the contingent consideration payables were determined using discounted cash flow method and are within Level 3 fair value measurement.

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 19. REDEMPTION LIABILITIES ON NON-CONTROLLING INTERESTS

In January 2021, Boan Biotech, a subsidiary of Shandong Luye Pharmaceutical Co., Ltd. ("Shandong Luye"), completed financing from 18 third-party investors ("Investors") at a total consideration of RMB876,618,000. Significant terms of the subscription agreements that will impact the accounting treatment of the Group are outlined below:

Redemption rights held by non-controlling shareholders:

Pursuant to the subscription agreements signed by and among Investors, the Company, and Shandong Luye, shares of the Investors shall be redeemable by Shandong Luye upon the occurrence of certain contingent events which cannot be controlled by Boan Biotech, Shandong Luye and the Company, including: (i) a qualified public offering of Boan Biotech cannot be completed by 31 December 2024; (ii) a qualified public offering of Boan Biotech cannot be achieved due to material integrity issue of existing shareholders, directors or senior managements, or due to material internal control weaknesses resulted from existing shareholders or management; (iii) a qualified public offering of Boan Biotech cannot be achieved due to the auditor does not give an unqualified opinion; or (iv) the Group does not receive approval in connection with the application of proposed spin-off listing of Boan Biotech from the SEHK.

The redemption price shall be determined by Investors based on 1) the amount that would give Investors a ten percent internal return rate for their investments in Boan Biotech plus all accrued but unpaid dividends; or 2) the then fair value of shares held by the Investors, and in any case the redemption price shall be not greater than three times of the respective investor's total contribution amount. The put option granted to non-controlling shareholders give rise to financial liabilities.

	<b>Redemption liabilities</b> (Unaudited) RMB'000
At 1 January 2021	—
Recognition	925,277
Changes in fair value	27,473
At 30 June 2021	952,750

The fair values of the redemption liabilities were determined using discounted cash flow method and are within Level 3 fair value measurement. Significant unobservable input to the valuation of redemption liabilities on non-controlling interests is as follows:

Discount rate 7.6%

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 20. CONTINGENT LIABILITIES

A subsidiary of the Group is currently involved in an arbitration brought by the former distributor of Seroquel in Mainland China disputing the subsidiary's basis of terminating the distribution agreement with such distributor. The directors of the Company, based on information currently available to the Group and preliminary assessment taking into account the advice from the Group's legal counsel in relation to the arbitration proceedings, believe that the subsidiary has a valid defence against the allegation and, accordingly, the group has not provided for any claim arising from the litigation, other than the related legal and other costs.

## 21. COMMITMENTS

The Group had the following capital commitments as at the end of the reporting period:

	<b>30 June 2021 (Unaudited) RMB'000</b>	31 December 2020 (Audited) RMB'000
Contracted, but not provided for:		
Buildings	301,482	358,945
Plant and machinery	376,982	321,089
Other intangible assets	51,681	52,199
	<b>730,145</b>	732,233

## 22. RELATED PARTY TRANSACTIONS

Details of the Group's principal related parties are as follows:

Company	Relationship
Steward Cross Pte. Ltd. ("Steward Cross")	Associate
Shandong International Biotech Park Development Co., Ltd. ("Biotech Park Development")	An entity controlled by the controlling shareholder
Luye Investment Group Co. Ltd. ("LIG")	An entity controlled by the controlling shareholder
Luye Boston R&D LLC. ("Luye Boston")	An entity controlled by the controlling shareholder

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 22. RELATED PARTY TRANSACTIONS (Continued)

- (a) The Group had the following transactions with related parties during the six months ended 30 June 2021 and 2020:

	Notes	For the six months ended 30 June	
		2021 (Unaudited) RMB'000	2020 (Unaudited) RMB'000
Sales of products to:			
Steward Cross	(i)	4,546	2,663
Interest income from:			
LIG	(ii)	—	1,283
Receipts of repayments from:			
LIG	(ii)	—	103,795
Lease from:			
Biotech Park Development	(iii)	1,147	1,206
Luye Boston	(iii)	1,101	—
		<b>2,248</b>	1,206

Notes:

- (i) The sales to Steward Cross were made according to the published prices and conditions offered to the major customers of the Group.
- (ii) The loans bear interests of 4.35% to 6.18% per annum.
- (iii) The service fees were charged with reference to prices mutually agreed between the parties.

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 22. RELATED PARTY TRANSACTIONS (Continued)

(b) Outstanding balances with related parties:

	Note	30 June 2021 (Unaudited) RMB'000	31 December 2020 (Audited) RMB'000
<b>Due from related parties</b>			
Steward Cross	(i)	1,186	—
<b>Due to related parties</b>			
Biotech Park Development	(i)	2,701	2,196
Luye Boston	(i)	1,721	—
		4,422	2,196

Note:

(i) The balances are unsecured, interest-free and have no fixed terms of repayment.

## 23. SHARE-BASED PAYMENTS

### Share award scheme

The Company adopted a share award scheme on 10 January 2017 (the “Scheme” or “Luye Pharma Share Award Scheme”). The purpose of the Scheme is to recognise contributions by certain employees, including any executive director of any member of the Group except for the current executive directors and to provide them with incentives in order to retain them for the continuing operation and development of the Group and to attract suitable personnel for the further development of the Group.

Subject to any early termination as may be determined by the board of directors in accordance with the rules of the Scheme, the Scheme shall be valid and effective for a term of ten years commencing on 10 January 2017 (the “Adoption Date”).

The Scheme shall be administered by the board of directors and Bank of Communications Trustee Limited (the “Trustee”) in accordance with the rules of the Scheme and the trust deed in respect of the Scheme to be entered into between the Company and the Trustee (the “Trust Deed”). The decision of the board of directors with respect to any matter arising under the Scheme (including the interpretation of any provision) shall be final and binding. The Trustee will hold the Company’s shares in accordance with the terms of the Trust Deed. The Trustee may not exercise the voting rights in respect of any Shares held under the Trust.

The board of directors may from time to time cause to be paid an amount to the Trustee by way of settlement or otherwise contributed by the Company or other member of the Group as directed by the board of directors. The committee appointed and authorised by the board of directors to administer the Scheme, which shall consist of three members of the senior management of the Company to be appointed by the board of directors, may from time to time instruct the Trustee in writing to purchase shares on the Stock Exchange specifying the timing of purchase, maximum amount of funds to be used and the range of prices within which such shares are to be purchased.

## 23. SHARE-BASED PAYMENTS (Continued)

### Share award scheme (Continued)

The board of directors may from time to time select any employee (excluding any employee who is resident in a place where the award of, in respect of a selected employee, such number of shares awarded by the Board (the "Awarded Shares") and/or the vesting and transfer of the Awarded Shares pursuant to the terms of the Scheme is not permitted under the laws or regulations of such place or where in the view of the board of directors or the Trustee of the Scheme, compliance with applicable laws or regulations in such place makes it necessary or expedient to exclude such employee) for participation in the Scheme as a selected employee and grant to such selected employee Awarded Shares in such number at a stated price at which an Award Share is granted to a selected employee (the "Grant Price") and on and subject to such terms and conditions as it may in its discretion determine.

The board of directors is entitled to impose any conditions as it deems appropriate in its discretion with respect to the vesting of the Awarded Shares on the selected employee. Upon the vesting of the Awarded Shares, the selected employee may elect to have the Awarded Shares transferred to him or effect the sale of the Awarded Shares and receive the net proceeds from such sale. In either case, the selected employee shall pay the Company the Grant Price for the Awarded Shares.

A selected employee will not have any interest or rights (including the right to vote at general meetings of the Company or the right to receive dividends) in the Awarded Shares prior to, in respect of a selected employee, the date on which his entitlement to the Awarded Shares is vested in such selected employee pursuant to the terms of the Scheme (the "Vesting Date"). Prior to the Vesting Date, any award of Awarded Shares is personal to the selected employee to whom it is made and is not assignable and no selected employee may in any way sell, transfer, charge, mortgage, encumber or create any interest in favour of any other person over or in relation to the Awarded Shares referable to him pursuant to such award. In the event that a selected employee has ceased to be an employee, the relevant award made to such selected employee will automatically lapse and the relevant Awarded Shares will remain part of the funds under the Trust.

The Scheme will terminate on the earlier of (i) the 10th anniversary date of the Adoption Date; and (ii) such date of early termination as determined by the board of directors provided that such termination shall not materially and adversely affect any subsisting rights of any selected employee.

The fair value of services received in return for shares granted is measured by reference to the fair value of shares granted. The fair value of the share option is measured based on the general accepted valuation procedures and practices that rely substantially on the use of numerous assumptions and the consideration of many uncertainties.

Pursuant to share award notices issued on 15 May 2017 to those selected employees, an aggregate of 17,724,000 shares (the "2017 Awarded Shares") of the Company of US\$0.02 each were granted at the consideration of HK\$4 for each share and the earliest vesting date of the 2017 Awarded Shares is 15 May 2020. There is no other performance target required except the eligible participant remains as an employee of the Group during the vesting period and meet the expectation of the Company on daily performance.

Pursuant to share award notices issued on 15 May 2018 to those selected employees, an aggregate of 20,098,000 shares (the "2018 Awarded Shares") of the Company of US\$0.02 each were granted at the consideration of HK\$4 for each share and the earliest vesting date of the 2018 Awarded Shares is 15 May 2021. There is no other performance target required except the eligible participant remains as an employee of the Group during the vesting period and meet the expectation of the Company on daily performance.

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 23. SHARE-BASED PAYMENTS (Continued)

### Share award scheme (Continued)

Pursuant to share award notices issued on 15 May 2019 to those selected employees, an aggregate of 25,206,000 shares (the "2019 Awarded Shares") of the Company of US\$0.02 each were granted at the consideration of HK\$4 for each share and the earliest vesting date of the 2019 Awarded Shares is 15 May 2022. There is no other performance target required except the eligible participant remains as an employee of the Group during the vesting period and meet the expectation of the Company on daily performance.

The following awarded shares were outstanding under the Scheme during the period:

	Number of shares held for the Scheme	Number of awarded shares
At 1 January 2021	7,019,500	58,479,000
Forfeited	5,955,000	(5,955,000)
At 30 June 2021	12,974,500	52,524,000
Exercisable as at 30 June 2021	—	34,569,000
	Number of shares held for the Scheme	Number of awarded shares
At 1 January 2020	2,470,500	63,028,000
Forfeited	4,549,000	(4,549,000)
At 31 December 2020	7,019,500	58,479,000
Exercisable as at 31 December 2020	—	16,474,000

The Group recognised a share-based payment expense of RMB18,431,000 during the period (the six months ended 30 June 2020: RMB31,984,000). Out of the share-based payment expense, an amount of RMB103,000 was included in the directors' remuneration (the six months ended 30 June 2020: RMB247,000).

## 23. SHARE-BASED PAYMENTS (Continued)

### Share-based payment scheme of Boan Biotech

Boan Biotech operates a share-based payment scheme to promote development of business, motivate long-term strategy achievement and provide incentives and rewards to the eligible employees. The awarded shares were granted through Yantai Bo Lian Investment Center LLP (“Bo Lian”), Yantai Bo Sheng Investment Center LLP (“Bo Sheng”) and Yantai Bo Fa Investment Center LLP (“Bo Fa”).

On 27 January 2021, 100% equity interest in Bo Lian was granted to 1 general partner and 35 selected employees for a consideration of RMB64,140,000. 100% equity interest in Bo Sheng was granted to 1 general partner and 44 selected employees for a consideration of RMB44,790,000. 100% equity interest in Bo Fa was granted to 1 general partner and 46 selected employees for a consideration of RMB33,750,000. There is no performance target required except the eligible participant remains as an employee of the Group during the vesting period.

Shares granted to the grantees shall be restricted within 36 months from the date of Boan Biotech’s qualified listing (“lockup period”). 25% of the shares granted shall become unrestricted to the grantees after 12 months since the end of the lockup period. 25% of the shares granted shall become unrestricted to the grantees after 24 months since the end of the lockup period. 25% of the shares granted shall become unrestricted to the grantees after 36 months since the end of the lockup period. 25% of the shares granted shall become unrestricted to the grantees after 48 months since the end of the lockup period.

The Group recognised a share-based payment expense of RMB7,064,000 during the period.

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 24. FINANCIAL INSTRUMENTS BY CATEGORY

The carrying amounts of each of the categories of financial instruments as at 30 June 2021 and 31 December 2020 are as follows:

**As at 30 June 2021 (Unaudited)**

### Financial assets

	Financial assets at fair value through profit or loss		Financial assets at fair value through other comprehensive income	Financial assets at amortised cost	Total
	Designated as such upon initial recognition	Mandatorily designated as such			
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Equity investments designated at fair value through other comprehensive income	—	—	98,886	—	98,886
Notes receivable	—	—	318,953	—	318,953
Trade receivables	—	—	—	1,449,772	1,449,772
Financial assets included in prepayments, other receivables and other assets	—	—	—	259,635	259,635
Financial assets at fair value through profit or loss	1,263	1,249,141	—	—	1,250,404
Cash and cash equivalents	—	—	—	4,943,646	4,943,646
Time deposits with original maturity of over three months	—	—	—	150,000	150,000
Pledged time deposits	—	—	—	1,804,768	1,804,768
Long-term receivables	—	—	—	8,000	8,000
Restricted cash	—	—	—	36,834	36,834
Due from related parties	—	—	—	1,186	1,186
	1,263	1,249,141	417,839	8,653,841	10,322,084

### Financial liabilities

	Financial liabilities at fair value through profit or loss		Financial liabilities at amortised cost	Total
	Designated as such upon initial recognition	Held for trading		
	RMB'000	RMB'000	RMB'000	RMB'000
Trade and notes payables	—	—	722,619	722,619
Financial liabilities included in other payables and accruals	—	—	380,642	380,642
Due to related parties	—	—	4,422	4,422
Convertible bonds	—	—	1,843,264	1,843,264
Long-term payables	—	—	51,681	51,681
Interest-bearing bank and other borrowings	—	—	7,063,588	7,063,588
Redemption liabilities on non-controlling interests	952,750	—	—	952,750
Contingent consideration payables	322,481	—	—	322,481
	1,275,231	—	10,066,216	11,341,447

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 24. FINANCIAL INSTRUMENTS BY CATEGORY (Continued)

The carrying amounts of each of the categories of financial instruments as at 30 June 2021 and 31 December 2020 are as follows: (Continued)

As at 31 December 2020 (Audited)

### Financial assets

	Financial assets at fair value through profit or loss		Financial assets at fair value through other comprehensive income	Financial assets at amortised cost	Total
	Designated as such upon initial recognition	Mandatorily designated as such			
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Equity investments designated at fair value through other comprehensive income	—	—	61,556	—	61,556
Notes receivable	—	—	602,614	—	602,614
Trade receivables	—	—	—	950,475	950,475
Financial assets included in prepayments, other receivables and other assets	—	—	—	253,522	253,522
Financial assets at fair value through profit or loss	1,263	1,431,907	—	—	1,433,170
Cash and cash equivalents	—	—	—	3,865,385	3,865,385
Time deposits with original maturity of over three months	—	—	—	109,000	109,000
Pledged time deposits	—	—	—	2,190,776	2,190,776
Restricted cash	—	—	—	37,473	37,473
Long-term receivables	—	—	—	8,000	8,000
	1,263	1,431,907	664,170	7,414,631	9,511,971

### Financial liabilities

	Financial liabilities at fair value through profit or loss		Financial liabilities at amortised cost	Total
	Designated as such upon initial recognition	Held for trading		
	RMB'000	RMB'000	RMB'000	RMB'000
Trade and notes payables	—	—	485,262	485,262
Financial liabilities included in other payables and accruals	—	—	458,664	458,664
Due to related parties	—	—	2,196	2,196
Convertible bonds	—	—	1,810,930	1,810,930
Long-term payables	—	—	52,199	52,199
Interest-bearing bank and other borrowings	—	—	8,170,570	8,170,570
Derivative financial instruments	—	22,563	—	22,563
Contingent consideration payables	638,556	—	—	638,556
	638,556	22,563	10,979,821	11,640,940

## 25. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

During the reporting period, the fair values of the Group's financial instruments approximated to their respective carrying amounts.

The Group's finance department headed by the finance manager is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance manager reports directly to the chief financial officer and the audit committee. At each reporting date, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the chief financial officer. The valuation process and results are discussed with the audit committee twice a year for interim and annual financial reporting.

Management has determined that the carrying amounts of cash and cash equivalents, pledged time deposits, restricted cash, trade receivables, other receivables and other assets, amounts due from related parties, trade and notes payables, other payables and short-term interest-bearing bank and other borrowings, based on their notional amounts, reasonably approximate to their fair values because these financial instruments are mostly short term in nature.

The fair values of the non-current portion of pledged time deposits, interest-bearing loans and other borrowings, long-term receivables and payables have been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities. The Group's own non-performance risk for interest-bearing bank borrowings and lease liabilities as at the end of the reporting period was assessed to be insignificant. The fair value of the liability portion of the convertible bonds is estimated by discounting the expected future cash flows using an equivalent market interest rate for a similar convertible bond with consideration of the Group's own non-performance risk.

The fair values of listed equity investments are based on quoted market prices. The fair values of unlisted equity investments designated at fair value through other comprehensive income are based on recently executed transaction prices in securities of the issuer. The fair value of the unlisted equity investment at fair value through profit or loss has been estimated using a market-based valuation technique based on assumptions that are not supported by observable market prices or rates. The valuation requires the management to determine comparable public companies (peers) based on industry, size, leverage and strategy, and calculates an appropriate price multiple, which is price to book value ("P/B") multiple, for each comparable company identified. The multiple is calculated by dividing the enterprise value of the comparable company by a book value measure. The trading multiple is then discounted for considerations such as illiquidity and size differences between the comparable companies based on company-specific facts and circumstances. The discounted multiple is applied to measure the fair value of the unlisted equity investment. The management believes that the estimated fair value resulting from the valuation technique, which is recorded in the consolidated statement of financial position, and the related change in fair values, which is recorded in the consolidated statement of profit and loss, are reasonable, and that it was the most appropriate value at the end of the reporting period.

The Group invests in unlisted investments, which represent wealth management products issued by banks in Mainland China. The Group has estimated the fair value of these unlisted investments by using a discounted cash flow valuation model based on the market interest rates of instruments with similar terms and risks.

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 25. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

The fair values of the notes receivable classified as financial assets at fair value through other comprehensive income as at 30 June 2021 have been calculated by discounting the expected future cash flows, which are the par values of the notes receivable. In addition, the notes receivable will mature within twelve months, thus their fair values approximate to their carrying values.

The fair values of the contingent consideration payables and redemption liabilities on non-controlling interests were determined using discounted cash flow method and are within Level 3 fair value measurement.

Set out below is a summary of significant unobservable inputs to the valuation of financial instruments together with a quantitative sensitivity analysis as at 30 June 2021:

	Valuation technique	Significant unobservable inputs	Weighted average rate	Sensitivity of fair value to the input
Contingent consideration payables	Discounted cash flow method	Discount rate	4.9%	0.1% increase/decrease in discount would result in decrease/ increase in fair value by RMB486,000/RMB487,000
		Discount for own non-performance risk	5%	1% increase/decrease in discount would result in decrease/ increase in fair value by RMB2,583,000/RMB2,577,000
Redemption liabilities on non-controlling interests	Discounted cash flow method	Discount rate	7.6%	0.1% increase/decrease in discount would result in decrease/ increase in fair value by RMB3,098,000/RMB3,111,000

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 25. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

### Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value:

**As at 30 June 2021 (Unaudited)**

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Equity investments designated at fair value through other comprehensive income	2,780	96,106	—	98,886
Notes receivable	—	318,953	—	318,953
Financial assets at fair value through profit or loss	16,150	1,232,991	1,263	1,250,404
	18,930	1,648,050	1,263	1,668,243

**As at 31 December 2020 (Audited)**

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Equity investments designated at fair value through other comprehensive income	3,041	58,515	—	61,556
Notes receivable	—	602,614	—	602,614
Financial assets at fair value through profit or loss	19,248	1,412,659	1,263	1,433,170
	22,289	2,073,788	1,263	2,097,340

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

## 25. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

### Fair value hierarchy (Continued)

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments: (Continued)

Liabilities measured at fair value:

As at 30 June 2021 (Unaudited)

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Contingent consideration payables	—	—	322,481	322,481
Redemption liabilities on non-controlling interests	—	—	952,750	952,750
	—	—	1,275,231	1,275,231

As at 31 December 2020 (Audited)

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Contingent consideration payables	—	—	638,556	638,556
Derivative financial instruments	—	22,563	—	22,563
	—	22,563	638,556	661,119

During the period, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and financial liabilities (the six months ended 30 June 2020: Nil).